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INVESTIGATIONS OF TELOMERES AND TELOMERASE FOLLOWING IONIZING 
RADIATION EXPOSURE 
 
 Telomeres are critical structures located at the termini of eukaryotic chromosomes that 
regulate the replicative lifespan of human cells. Telomeres shorten with cell division, a process 
that eventually leads to telomere based growth arrest and cellular senescence. Telomere length is 
maintained through the activity of the reverse transcriptase, telomerase that functions in 
embryonic and adult stem cells to elongate telomeres and prolong replicative lifespan. 
Telomerase is repressed in the vast majority of human somatic cells, and its reactivation is a 
critical early step in carcinogenesis. Thus, telomerase and telomere maintenance are critical 
factors in the processes of carcinogenesis, tumor maintenance, and tumor recurrence following 
interventional therapy.      
 Ionizing radiation (IR) has long been acknowledged as both a potent carcinogen and an 
effective agent in the treatment of cancer. To investigate the role telomeres and telomerase play 
in the cellular response to IR exposure, we tracked telomerase activity and telomere length in a 
panel of cancer and immortalized non-cancer cell lines following both acute and low dose rate 
(LDR) exposures to γ-rays. We observed elevations of telomerase activity in cancer, but not non-
cancer, cell lines following acute exposures to IR. Further, telomere length was significantly 
reduced in both cancer and non-cancer cells post-acute IR exposure. Taken together, these 
studies suggest telomerase activity is playing a role in accelerated tumor repopulation following 
iii 
 
radiation therapy and that the associated telomere loss may be contributing to genomic 
instability.  
 As IR induced enrichment of cancer stem cells (CSC) in established cancer cell lines was 
recently suggested to play a role in accelerated tumor repopulation following radiation therapy, 
we investigated a potential role for telomerase in the IR induced enrichment of CSCs. Consistent 
with previous reports, we detected a significant enrichment of putative breast CSCs in MCF-7 
mammary carcinoma cells at 5 days post exposure, and demonstrate significant enrichment of 
putative CSCs in the non-tumorigenic MCF-10a, WTK1, and LCL15044 cell lines. Further small 
molecule inhibition of telomerase activity was able to effectively block CSC enrichment in both 
MCF-7 and MCF-10a cells. Together, these results suggest that telomerase inhibition is a 
significant player in the IR induced enrichment of putative CSCs in both cancer and non-cancer 
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Telomeres and Telomerase 
 
Telomere Structure and Function 
 
Telomeres are nucleoprotein complexes located at the termini of linear, eukaryotic 
chromosomes. The human telomere sequence, conserved throughout vertebrate biology, consists 
of the tandem repeat DNA sequence 5’-TTAGGG-3’ (Meyne, Ratliff, & Moyzis, 1989), which is 
directly bound by Telomere Repeat Factor 1 (TRF1), Telomere Repeat Factor 2 (TRF2), and 
Protection of Telomeres 1 protein (POT1), and together with TRF1 Interacting Nuclear Factor 1 
(TIN2), Tripeptidyl Peptidase 1 (TPP1), and Replication Associated Protein 1 (Rap1) form a 
tightly regulated chromatin structure termed Shelterin (de Lange, 2005). The telomeric DNA 
sequence ends in a 3’ single stranded overhang, which with the help of the shelterin complex, 
folds back onto itself and invades the double stranded telomeric DNA duplex forming a lariat 
structure known as the T-loop (Griffith et al., 1999). A schematic of the T-loop structure can be 
found in Figure 1.1. It is believed that this T-loop structure serves to protect the end of the 
chromosome from nucleolytic degradation, in addition to preventing the telomere (essentially a 
naturally occurring double strand DNA break) from being recognized as a break in need of repair 
(Bailey, 2008).  
Due to the semi-conservative nature of DNA replication and the requirement for an RNA 
primer in lagging strand DNA synthesis, conventional DNA polymerases are unable to replicate 
to the absolute end of the chromosome (Olovnikov, 1973; Watson, 1972). This phenomenon has 




sequence with each round of cell division (Counter et al., 1992; Prowse & Greider, 1995; Vaziri 
et al., 1993). Telomere loss accompanies cell division and aging (Cherif, Tarry, Ozanne, & 
Hales, 2003; Harley, Futcher, & Greider, 1990), and is the molecular mechanism underlying the  
finite replicative lifespan of human somatic cells known as the Hayflick Limit (Hayflick & 
Moorhead, 1961). As telomeres shorten, they eventually reach a state of critical shortness, which 
triggers a persistent DNA damage response resulting in cellular senescence or apoptosis, thus 
signaling the end of the cell’s replicative lifespan (Bodnar et al., 1998; Harley & Villeponteau, 
1995). Telomere shortening and defects in telomere length maintenance have been linked to 
diseases of premature aging  including Werner syndrome, as well as degenerative diseases such 
as idiopathic pulmonary fibrosis (IPF) and dyskeratosis congenital (DKC) (H. Zhu, Belcher, & 
van der Harst, 2011). Alternatively, cancer cells which require a mechanism to maintain telomere 
length in order to avoid a state of crisis, utilize the activity of the reverse transcriptase telomerase 
to synthesize telomeric DNA de novo; thereby overcoming the end replication problem and 
acquiring replicative immortality. We now recognize telomeres and telomere biology as critical 
players situated at the crossroads between normal human aging, degenerative disease, and 
cancer. 
 
Telomeres and Telomerase History and Significance 
 
Telomeres were first functionally described circa 1931 when Barbara McClintock and 
Herman Muller, working in maize and drosophila respectively, utilized x-rays to fragment 
chromosomes and noticed that the natural ends of chromosomes are functionally different than 
those existing at the site of an induced chromosomal break (McClintock, 1938; Muller, 1938).  
While McClintock and Muller lacked the necessary tools to understand the structure of 




1950’s (Watson & Crick, 1953), and the discovery of DNA polymerases by Arthur Kornberg in 
the late 1950’s (Kornberg, 1957) lead to the realization of end replication problem, and further, 
how was it solved at telomeres? Elizabeth Blackburn sought to answer this question, and 
working in Tetrahymena thermophilia, demonstrated that telomeres were composed of a tandem 
repeat DNA sequence varying between 20 to 70 repeats (Blackburn & Gall, 1978). The 
conserved, repeat nature of telomeric DNA was later confirmed by Blackburn and colleagues in 
Saccharomyces cerevisae, indicating that telomere structure transcends the boundaries of 
kingdoms in the evolutionary spectrum (Szostak & Blackburn, 1982). We now appreciate that 
the structure and function of telomeric DNA, while varying in sequence and associated proteins, 
is conserved throughout domain Eukarya (Blackburn, Greider, & Szostak, 2006). While the 
structural nature of telomeric DNA had been described in model organisms, a fundamental 
solution to the end replication problem remained unknown. Working as a graduate student under 
Blackburn, Carol Greider began a series of experiments to identify the mystery enzyme capable 
of synthesizing telomeric DNA.  In December of 1984, Greider confirmed the existence of such 
an enzyme, which was capable of adding 6-base pair repeats to a specified oligonucleotide 
consistent with the Tetrahymena telomere sequence (Greider & Blackburn, 1985). Blackburn and 
Greider later termed this enzyme “telomerase.” Telomerase is now appreciated as a reverse 
transcriptase complex consisting of a catalytic protein component, the telomerase reverse 
transcriptase (TERT), and a telomerase RNA template component (TERC) both of which are 
essential for the elongation activity of telomerase to occur (Autexier & Lue, 2006). Thus 
telomerase is an enzyme capable of circumventing the end replication problem by preventing 




Soon thereafter, the race to identify the human telomere sequence ended with the 
identification of the repetitive TTAGGG sequence via fluorescence in situ hybridization (FISH) 
(Moyzis et al., 1988). Together with the discovery of telomerase, an explosion of research was 
ignited that sought to characterize telomeres and telomerase in a variety of organisms and 
settings. A critical role for telomerase in cancer was confirmed in cultured cancer lines and 
telomerase knockout mouse models, in which loss of telomerase activity limited cell division and 
tumor production (Blackburn et al., 2006). These and numerous other studies have led to the 
development of telomere based therapies in the clinic, most specifically telomerase inhibitors 
which are now undergoing Phase III clinical trials for human use (Thompson et al., 2013). 
Additionally, DNA repair inhibitors such as phosphatidylinositol 3 kindase (PIK3) and poly 
ADP-ribose polymerase (PARP) inhibitors also show promise.    
Blackburn, Greider, and their collaborator Jack Szostak were awarded the Nobel Prize for 
Medicine and Physiology in 2009 for the discovery of telomeres and telomerase; highlighting the 
important role that these discoveries have played not only in our understanding of the critical 
biological processes surrounding the nature of chromosome ends, but also the role they have 
played in the study and treatment of human disease.  
 
Stem Cell Biology 
 
Stem cells or progenitor cells are defined as having the potential to mitotically divide and 
develop into many different cell types (Health, 2009). An early example of stem cell theory was 
conducted in 1961 when it was determined that only a small percentage of bone marrow cells 
were able to form colonies in the spleen on nude mice (Till & Mc, 1961). In many tissues, stem 
cells serve as an internal repair system dividing with few limits to replenish lost or damaged cells 




remain a stem cell or differentiate into another type of cell with a more specialized function, a 
process known as asymmetric cell division (Morrison & Kimble, 2006). Stem cells are also 
capable of self-renewal undergoing symmetric cell division to produce equivalent daughter stem 
cells (Q. Z. Wang, Lu, Jiang, Diao, & Xu, 2010). Experimentally, stem cells can be coaxed to 
differentiate into various specialized cell types under different microenvironmental or 
experimental conditions (Sokolov & Neumann, 2013). These properties of self-renewal and the 
ability to differentiate along multiple lineages (potency) are defining characteristics of stem cells 
(Mitalipov & Wolf, 2009). Historically, stem cells have been divided into two categories, 
embryonic stem cells (ESCs) and adult (somatic) stem cells (Health, 2009).  
ESCs are defined as primitive (undifferentiated) cells derived from pre-implantation 
embryos capable of dividing for prolonged periods of time without differentiation in culture 
(Health, 2009). These are considered pluripotent stem cells, in that they have the potential to 
develop into cells of any of the three germ layers; ectoderm, mesoderm, or endoderm and can 
give rise to any fetal or adult cell type (Mitalipov & Wolf, 2009). ESCs were first isolated from 
the blastocysts of murine embryos in 1981 (Martin, 1981), and human ESCs (hESCs) were 
derived using an analogous method in 1998 (Thomson et al., 1998). Early embryonic stem cells 
and cell lines were derived for the purpose of in vitro fertilization techniques and later donated 
with informed consent for research purposes (Health, 2009). ESCs were the first type of stem 
cell line to be derived and cultured from humans, however ethical issues associated with the 
production of these cell lines has limited their use as a research tool.    
Adult or somatic stem cells are rare undifferentiated cells found among specialized cell 
types in many organs and differentiated tissues with a limited capacity for self-renewal and 




into a limited number of cell types (Mitalipov & Wolf, 2009). For example a blood or 
hematopoietic stem cell is able to differentiate into lymphocytes and monocytes but not muscle 
or brain cells. Differentiation of these cells is generally limited to the specialized cells within the 
organ of origin and their role is generally limited to maintaining and repairing the tissue in which 
they reside (Mitalipov & Wolf, 2009).     
Stem cells, self-renewal, differentiation, and potency are concepts central to 
developmental biology and organismal structure. Gaining a deeper understanding and 
broadening the clinical applications of these concepts has potential implications for regenerative 
medicine, treatment of degenerative disease, and cancer therapy.    
 
Telomeres and Telomerase in Aging, Degenerative Disease, and Cancer 
 
In the absence of a mechanism to elongate telomeres, the end replication problem leads to 
a progressive shortening of telomeres eventually triggering senescence (Blasco, 2005). During 
embryonic development ESCs express the human telomerase holoenzyme, which contains both 
the human TERT component (hTERT) and the human telomeric RNA component (hTERC), in 
addition to numerous other proteins which aid in telomerase function (Choudhary, Karande, & 
Raghavan, 2012). As ESCs divide and begin to differentiate, telomerase expression is reduced 
and eventually suppressed around the time of birth, as evidenced by the fact that telomerase 
transcription is repressed in the vast majority of human somatic cells (Flores & Blasco, 2010). 
The exceptions to this rule include cells of the germ-line which express telomerase to a high 
degree and adult stem cells which express lower levels of telomerase necessary for their 
elongated replicative lifespan (Shay & Wright, 2011). Figure 1.2 details a schematic of telomere 




replicative lifespan of human cells and lies at the crux between aging, degenerative disease, stem 
cell maintenance, and tissue self-renewal. 
Loss of telomerase function has been associated with multiple degenerative diseases and 
diseases of tissue failure including dyskeratosis congenita (DKC) and idiopathic pulmonary 
fibrosis (IPF) (Garcia, Wright, & Shay, 2007). DKC is a rare multisystem disorder characterized 
by skin pigmentation, nail dystrophy, and leukoplakia in the mouth (Drachtman & Alter, 1995). 
Patients appear normal at birth but develop somatic disorders of the bone marrow, 
gastrointestinal tract, endocrine system, and neurological systems within the first two decades, 
leading to death. About 40% of DKC cases involved a mutation in genes related to telomere 
function (Vulliamy et al., 2006) and positional cloning in patients diagnosed with DKC 
identified a common mutation in the DKC1 gene encoding dyskerin which is associated with 
telomerase (Heiss et al., 1998). Dyskerin aids in the processing of hTERC into mature RNA and 
loss of function results in decreased hTERC levels and shortened telomeres (Mitchell, Wood, & 
Collins, 1999; J. M. Wong & Collins, 2006). Thus mutations in DKC1 caused decreased levels 
of hTERC lead to a defect in telomerase that result in progressive DKC, eventually triggering 
fatal bone marrow failure. IPF is a progressive, fatal lung disease characterized by abnormal lung 
scarring and inefficient gas exchange (Gross & Hunninghake, 2001). A small subset of patients 
have a familial form of the disease, and these familial cases tend to have nucleotide deletions in 
the hTERT gene leading to a truncated protein missing large portions of the reverse transcriptase 
domain (Tsakiri et al., 2007). In both DKC and IPF, loss of functional telomerase (presumably 
vital to adult stem cell compartments) results in progressive, genetic disease leading to tissue 




In contrast to differentiated human somatic cells and the degenerative diseases of 
telomerase failure highlighted above, cancer cells maintain their telomere length to prevent 
cellular senescence and crisis. The vast majority of cancers overcome this tumor suppressive 
barrier through the re-activation of telomerase (N. W. Kim et al., 1994; Shay, 2005; Shay & 
Wright, 2011). Ninety percent of human cancers express high levels of telomerase which 
maintains telomeres above a critically shortened length. The other ten percent of cancers 
maintain telomere length through a telomerase independent Alternative Lengthening of 
Telomeres (ALT) pathway (Heaphy et al., 2011). Therefore, telomere length maintenance is 
crucial to the survival of cancer cells, and all cancers must have a mechanism to maintain 
telomere length to sustain growth.  However, the mechanism of telomerase activation and the 
stage at which it becomes necessary for carcinogenesis to progress, remains in question and lies 
at the heart of one of the greatest controversies in cancer research: the multi-step or cell of origin 
models of carcinogenesis.  
The Armitage-Doll multistage model of carcinogenesis states that accumulated, heritable 
mutations in multiple genes over time provides a selective growth advantage leading to cancer  
(Armitage & Doll, 1954; Boyd & Barrett, 1990). As somatic cells divide, telomere shortening 
eventually triggers telomere based growth arrest and cellular senescence leading to an aging 
phenotype. However, in the presence of growth signals such as oncogene activation, cells with 
critically short telomeres will continue to divide until they reach a stage known as crisis, which is 
marked by critically short telomeres and telomere-telomere end fusions resulting in chromosome 
aberrations and mitotic cell death (Greenberg, 2005). This crisis phase is overcome via the 
reactivation of telomerase, which maintains telomeres at a length above the crisis levels, thereby 




multi-step model of carcinogenesis, telomerase reactivation prevents mitotic cell death resulting 
from telomere-telomere fusions in crisis endowing the cell with an essentially infinite replicative 
lifespan, providing a selective growth advantage, and facilitating tumor formation.    
Alternatively, the cell of origin or cancer stem cell (CSC) model of carcinogenesis states 
that cancer arises from mutations in the small population of adult stem cells that have a much 
greater replicative lifespan and are naturally more “cancer like” than differentiated somatic cells 
(Armanios & Greider, 2005). CSC’s are defined as possessing properties of indefinite self-
renewal, slow replication, intrinsic resistance to chemo- and radiotherapy and the ability to give 
rise to differentiated progeny (O'Flaherty et al., 2012). In this case, adult stem cells that already 
express telomerase can become deregulated through mutations in various genes, which are then 
propagated to the progeny of the adult stem cell that naturally has a large propensity for cell 
division. This eventually results in the generation of a bulk tumor containing both therapy 
resistant CSC’s, which function to renew the tumor following treatment, as well as differentiated 
non-stem cancer cells (NSCC’s). Pre-existing telomerase activity in adult stem cell populations 
give great replicative potential, which, through oncogenic mutation, transition to a CSC and 
drives tumor progression. 
Regardless of the model in which cancer arises, telomeres and telomerase are key players 
in regulating cellular lifespan. Therefore, a more comprehensive understanding of what 
processes and pathways telomeres and telomerase influence during carcinogenesis and cancer 
therapy will better inform both the treatment and prevention of cancer.  
 
Human Telomerase Function, Regulation, and Roles in Cancer 
 
The telomerase holoenzyme is a ribonucleoprotein composed of two primary 




(TERC) that acts as a template for the synthesis of telomeric repeats (Harrington et al., 1997; 
Weinrich et al., 1997). hTERT is encoded by a single gene located on the short arm of 
chromosome 5 at 5p15.33 and is roughly 40 kb in length containing 15 introns and 16 exons 
(NCBI website,(Cong, Wen, & Bacchetti, 1999). hTERC is located on the long arm of 
chromosome 3 at 3p26 (NCBI website) and the mature transcript contains 451 nucleotides 
(NCBI rna database) and is believed to be non-polyadenylated (Collins & Mitchell, 2002; D. Fu 
& Collins, 2003; Jady, Richard, Bertrand, & Kiss, 2006; Li & Blackburn, 2006). While hTERC 
expression is ubiquitous among different cell types, the expression of hTERT is tightly regulated. 
hTERT is expressed in adult stem cell compartments and embryonic stem cells, while its 
expression is repressed in somatic cells (Blasco, 2005). Additionally, cancer cells reactivate 
hTERT as a means of overcoming replicative senescence during carcinogenesis (Shay & Wright, 
2011). Transfection of hTERT into somatic cells extends the replicative lifespan and overcomes 
senescence (N. W. Kim et al., 1994), as well as increasing the invasive capacity of U2OS ALT, 
osteosarcoma cells (Yu et al., 2009). 
The protein encoded by hTERT is comprised of 1132 amino acid residues and is 
generally considered to have four distinct, functional domains (Autexier & Lue, 2006), which 
include the telomerase essential N-terminal (TEN) domain necessary for appropriate function of 
telomerase at the telomere (Autexier & Lue, 2006),  the TERT RNA-binding (TRB) domain that 
selectively binds TERC, the reverse transcriptase (RT) domain that contains the motifs necessary 
for hTERT’s reverse transcriptase activity, and the TERT C-terminal extension domain that 
participates in numerous protein-protein interactions and regulates enzyme localization and 




The mechanisms that regulate hTERT expression are poorly understood, however 
evidence for a cell signaling feedback network in which hTERT promotes its own transcription is 
beginning to emerge, that has implications for carcinogenesis and cancer treatment. Xiang et al. 
demonstrated that when hTERT was overexpressed in human lens epithelial cells, it induced an 
enhanced growth phenotype accompanied by a downregulation of the p53 and p21 tumor 
suppressor genes, which induced hyper-phosphorylation of the retinoblastoma protein (Rb) and 
upregulation of E2F transcriptional activity, thus promoting advancement of the cell cycle 
through the G1/M checkpoint (Xiang et al., 2002). Furthermore depletion of hTERT via RNA 
interference (RNAi) in human ovarian and breast cancer cells resulted in increased expression of 
p53 and p21 (Lai, Cunningham, Huynh, Andrews, & Tollefsbol, 2007).  It has also been 
demonstrated that overexpression of p53 represses telomerase activity (Kanaya et al., 2000), and 
that abrogation of p53 function induced cellular immortalization and the reactivation of 
telomerase (Yang et al., 2007). Taken together, these findings suggest a negative feedback loop 
between telomerase and the Rb/p53/E2F/p21 G1/M checkpoint machinery that may regulate 
hTERT expression throughout the cell cycle. 
hTERT expression has also been linked to the Wnt/β-catenin signaling network, which 
plays a significant role in the development of cancer (Anastas JN, 2013). Canonical Wnt 
signaling involves the accumulation of β-catenin in the cytoplasm, which then migrates into the 
nucleus where it acts as a transcriptional activator promoting the expression of genes that affect 
cell proliferation and differentiation including c-myc, oct4, sox2  and other oncogenes (Wu et al., 
2013). In the absence of Wnt ligand signaling, two proteins in the destruction complex, axin and 
adenomatous polyposis coli (APC), bind newly translated β-catenin and target it for 




β-catenin for ubiquitination and degradation by the proteasome, effectively preventing the 
transcription of its target genes. However, in the presence of Wnt ligand bound to frizzled 
receptors (FZD) on the cell surface, GSK3β kinase activity is repressed leading to a cytoplasmic 
and eventually a nuclear accumulation of β-catenin and therefore the transcription of β-catenin 
target genes (Wu et al., 2013).  
A link between TERT and the Wnt pathway was first uncovered in mouse skin cells 
expressing a catalytically inactive TERT, where it was demonstrated that stem cells expressing 
TERT protein exhibited transcriptional activation of genes regulated by Wnt and Myc (Choi et 
al., 2008). TERT was also shown to act as a cofactor for the β-catenin transcriptional complex in 
mouse embryonic stem cells (mES) (Park et al., 2009). In this study, TERT was shown to form a 
complex with the Wnt transcription factor BRG1/SMARCA4 that is a Switch/Sucrose Non 
Fermentable (SWI/SNF) related chromatin remodeling protein. This allowed TERT to physically 
occupy the promoters of Wnt target genes including cyclin D1 and c-myc and activate these 
reporter genes in culture and in vivo. It has also been demonstrated that β-catenin can directly 
regulate the expression of TERT, as β-catenin occupies the TERT promoter in human colorectal 
cancer cells (Hoffmeyer et al., 2012). hTERT was also shown to interplay with β-catenin  to 
facilitate cancer progression by inducing epithelial to mesenchymal transition (EMT) and CSC 
phenotype (Liu et al., 2013). Additionally, c-myc which is also under the control of Wnt/ β-
catenin signaling; is a well-known regulator of TERT transcription (Greider, 2012; Stower, 
2012). These studies provide evidence for a positive feedback loop between hTERT and Wnt/ β-
catenin signaling, however, a recent report by Elizabeth Blackburn’s group has generated 
controversy by questioning the direct interaction of β-catenin and the hTERT promoter 




Additionally, the telomere associated protein tankyrase 1 (TNKS) is a well-known 
regulator of the Wnt/ β-catenin signaling pathway. TNKS is an enzyme containing poly(ADP-
ribosylation) (PARP) activity that regulates the amount of TRF1 localized at telomeres (Hsiao & 
Smith, 2008; Smith, Giriat, Schmitt, & de Lange, 1998). TNKS adds PARP groups to TRF1, a 
modification that releases TRF1 from the telomere, thereby controlling access to and telomere 
elongation by telomerase (Smith & de Lange, 2000). Additionally, TNKS regulates Wnt/ β-
catenin signaling via modifications of axin; TNKS PARsylates the axin protein, which 
simultaneously targets it for degradation via the proteasome. Loss of axin results in an 
accumulation of β-catenin in the cytoplasm therefore activating the Wnt/ β-catenin signaling 
network even in the absence Wnt ligand being bound to Fzd receptors. Therefore, inhibition of 
TNKS PARP activity result the stabilization of axin, degradation of β-catenin, inhibits Wnt 





hTERT and hTERC are brought together and assembled into the telomerase holoenzyme 
at small nuclear sub-organelles known as Cajal bodies (Y. Zhao et al., 2011; Y. Zhu, Tomlinson, 
Lukowiak, Terns, & Terns, 2004). Cajal bodies are small and spherical, located in the nucleus 
and primarily identified by the presence of the protein coilin (Andrade et al., 1991). Cajal bodies 
are common in cells with high metabolism such as neurons and cancer and are thought to 
facilitate RNA biogenesis and maturation (Cremer & Cremer, 2001).   
hTERC is transcribed by RNA polymerase II and is believed to be non-polyadenylated 
(Gallardo & Chartrand, 2008). hTERC expression occurs in normal cells and its localization 




telomeres, Cajal bodies, or other nuclear structures (Y. Zhu et al., 2004). It was demonstrated 
that the localization of hTERC to Cajal bodies and telomeres is dependent on hTERT, whereas 
hTERT knockdown did not affect the overall level of hTERC expression, it did affect hTERC 
localization to hTERT, Cajal bodies, and telomeres (Tomlinson et al., 2008; Y. Zhu et al., 2004). 
Therefore it appears that the primary factor controlling localization of hTERC is the hTERT 
protein. Elevation of hTERC levels is an early step in the development of cancer and hTERC 
expression correlates better with cancer malignancy than the levels of hTERT expression or 
telomerase activity (Blasco et al., 1997). Additionally, numerous studies have shown that TERC 
polymorphisms correlate with breast cancer (Pellatt et al., 2013) and colorectal cancer risk (Jones 
et al., 2012). Single nucleotide polymorphisms (SNPs) (Chubb et al., 2013) and hTERC gene 
amplification (Eid et al., 2013; Nowak et al., 2006; Xu, Gruber, Peterson, & Pisa, 1998) have 
also been associated with risk of acute myelogenous leukemia (AML). Like hTERT, these 
findings suggest that hTERC functions not only as a part of canonical telomerase activity, but 
that it may also possess some additional functions important for carcinogenesis.  
Taken together, these findings suggest that the traditional role of telomerase in elongating 
telomeres is not the only important role it plays in carcinogenesis (Low & Tergaonkar, 2013). 
Throughout this project we will seek to assess the roles hTERT, hTERC, and telomeres play in 
the process of radiation induced carcinogenesis, as well as tumor repopulation following 




Introduction and Overview 
 
Ionizing radiation (IR) is a unique agent for which exposure is known to both drive 




energy to eject one or more orbital electrons from an atom or molecule (Hall, 2006). This is in 
contrast to non-ionizing or excitation radiation, which is able to raise orbital electrons to a higher 
energy state without actual ejection from the atom (Hall, 2006). Each ionization event results in 
the absorption of around 33 electron volts (eV), which is more than enough energy to break a 
strong (covalent) chemical bond (Hall, 2006). When occurring in living tissue, this breaking of 
chemical bonds results in damage to cellular structures including DNA, RNA, lipids, and 
proteins which can result in tissue injury, mutation, loss of function, and cell death.  This is the 
fundamental process driving both radiation carcinogenesis and therapeutic gains resulting from 
clinical radiation therapy in the treatment of cancer.  
  IR is generally classified as being either electromagnetic or particulate. Electromagnetic 
IR includes γ-rays and X-rays, which do not differ in their nature or properties, only in their 
atomic location of origin (Hall, 2006; Turner, 2007). γ-rays are produced intranuclearly (in the 
nucleus) and generally have higher energy whereas X-rays are produced extranuclearly (from 
changes in state of orbital electrons) and generally have lower energies. Particulate IR includes 
α-particles, electrons or β-particles, protons, neutrons, or larger heavy charged particles (HZE), 
which arise from the decay of unstable radio-isotopes or exist almost exclusively in the deep 
space environment (Turner, 2007). Most terrestrial exposures to IR result from galactic cosmic 
rays that penetrate the earth’s atmosphere, inhalation of radon generated from the natural decay 
of uranium in the earth, and medical diagnostic modalities (Hall, 2006). Radiation therapy on the 
other hand utilizes a combination of high energy photons and charged particles including 
electrons, protons, neutrons, and heavy charged particles such as carbon ions and neon ions 




The biological effects of IR exposure occur as a result of damage to critical targets. When 
radiation is absorbed inside a biological material, there is a stochastic probability that it will 
interact directly with critical molecular targets in the cell, which results in ionization events 
within the atoms of the critical target that can lead to chemical modification and result in a 
biological change. This is known as direct damage. Additionally IR can ionize the water 
surrounding critical targets, and generate free radicals and reactive oxygen species (ROS). ROS 
can diffuse throughout the aqueous solution surrounding critical targets and induce chemical 
alterations in critical targets. This is known as indirect damage. Both direct and indirect damage 
resulting from IR exposure can lead to cell death and other biological effects resulting from IR 
exposure (Hall, 2006).  
DNA is considered to be the principle target for the biological effects resulting from IR. 
IR induces base damage, single strand breaks (SSB), and most consequentially double strand 
breaks (DSB) to DNA, which when unrepaired or repaired incorrectly can lead to the formation 
of permanent changes such as chromosome aberrations, mutations, large scale deletions, and 
genomic instability. These changes all correlate with increasing IR dose and contribute to 
radiation induced cell death. Radiation induced cell death is defined as loss of function in 
differentiated, non-dividing cells, and as loss of reproductive integrity in proliferating cell 
populations. Loss of reproductive integrity is known as reproductive or mitotic cell death and is 
the primary end-point measured in vitro (Hall, 2006). 
The amount of damage induced by IR is generally proportional to its ionization density, 
which is traditionally measured by Linear Energy Transfer (LET). LET is defined as the rate of 
energy transferred per unit length along the radiation track and is generally denoted in units of 




2006). Photons, electrons, and high energy protons are generally considered low LET radiations 
whereas heavy ions, low energy protons, neutrons, and alpha particles are considered high LET 
radiations (Turner, 2007).   
While LET is a useful physical measurement for comparing radiation quality, it may not 
adequately reflect the variation of energy deposition along an ionization track. The relative 
biological effectiveness (RBE) is a more relevant tool to compare the differing biological effects 
of different radiation types, as RBE is defined as the ratio of the amount of a test radiation 
necessary to achieve the same quantifiable biological endpoint as a set amount of a reference 
radiation (usually 250 kV X-rays) (Hall, 2006). RBE depends on radiation quality, radiation 
dose, the fractionation or dose rate, and the biological end point examined.   
The effect of physical properties on RBE highlights the fact that all radiation, and 
therefore all radiation exposures, are not created equal. Specifically factors such as LET, dose-
rate, and dose fractionation significantly alter the response of a biological system to radiation.  
For example, while a dose response is generally observed for endpoints like survival, mutation, 
and chromosome aberrations, exposures to high acute doses/dose rates often exhibit lower 
incidences of oncogenic transformation, suggesting that low dose and low dose rate exposures 
may present a greater risk for carcinogenesis, the prevailing explanation is that dead cells cannot 
make tumors.  
 
Ionizing Radiation Induced Carcinogenesis 
 
Much of our understanding of the cancer risks associated with IR exposure arise from 
epidemiological studies that have tracked exposed individuals throughout their lifespans, the 
most notable of which is the Hiroshima and Nagasaki atomic bomb (A-bomb) survivors lifetime 




risk associated with IR exposure in medical, occupational, and environmental settings (Gilbert, 
2009).  
Leukemia was the first cancer to be linked with low LET radiation exposure in A-bomb 
surviors (Folley, Borges, & Yamawaki, 1952; Gilbert, 2009) and has the highest relative risk of 
any cancer. The risk of leukemia incidence decreases with age at time of exposure and with the 
number of years since that exposure occurred (Council, 2006; Preston et al., 2004). Essentially 
this highlights a complex relationship between age of IR exposure and cancer risk; exposure at 
younger ages carries an elevated risk of developing cancer later in life, a phenomenon that is 
near universal to IR induced cancers. Leukemia incidence in the A-bomb surviors peaked within 
the first 5-10 years following exposure and declined after that point, in contrast to the incidence 
of solid cancers, which had a latency period following exposure and increase in incidence with 
time since exposure (Gilbert, 2009).  Preston et al. reported that significant dose response 
relationships for cancers of the oral cavity, esophagus, stomach, colon, liver, lung, non-
melanoma skin, female breast, ovary, bladder, central nervous system, thyroid, and “all other 
solid cancers” among A-bomb survivors (Pawel, Preston, Pierce, & Cologne, 2008; Preston et 
al., 2008). Additional case control studies have confirmed a direct link between radiation dose 
and breast cancer risk (Ronckers, Erdmann, & Land, 2005), lung cancer risk (Pierce, Sharp, & 
Mabuchi, 2003), salivary gland tumors (Land et al., 1996), liver cancer(Cologne, Tokuoka, 
Beebe, Fukuhara, & Mabuchi, 1999), basal cell carcinoma (Ron et al., 1998), and tumors of the 
nervous system and pituitary gland (Preston, Ron, et al., 2002) among this cohort.  
In addition to environmental exposures such as those described in the A-bomb survivors 
study, medical exposures resulting from diagnostic imaging modalities and radiation therapy 




low and high LET exposures. An association between leukemia and medical treatment with 
radiation was first acknowledged in 1957 (Court-Brown & Doll, 2007). Since then numerous 
studies have found links between leukemia occurrence and radiation therapy (Boice et al., 1987; 
Weiss, Darby, Fearn, & Doll, 1995). Interestingly, the risk of leukemia first increases with dose 
then decreases as dose is escalated, suggesting cell killing in doses exceeding the 2 to 4 Gy range 
(Little et al., 1999). This is consistent with findings in patients treated for uterine cancer with 
brachytherapy in which relatively low dose and low dose rate exposures generated the same risk 
as those exposed to higher dose rate external beams, indicating that the low dose rate exposure is 
more carcinogenic than equivalent large, acute doses (Curtis et al., 1994; Travis et al., 1994).  
A dose-response relationship for breast cancer has also been demonstrated in numerous 
medical radiation studies. Preston et al. conducted a pooled analysis of breast cancer incidence 
from seven cohort studies of patients treated for benign disease and demonstrated a significant 
dose response with evidence of a downturn at high doses (Preston, Mattsson, et al., 2002). Case 
control studies of breast cancer risk in patients treated for malignant disease have revealed a 
significant dose response relationship for patients exposed under the age of 45 (Boice, Harvey, 
Blettner, Stovall, & Flannery, 1992; Hooning et al., 2008; Stovall et al., 2008). Elevated 
incidence of breast cancer has also been observed in Hodgkin Lymphoma (Travis et al., 2003; 
van Leeuwen et al., 2003) and childhood cancer survivors (Guibout et al., 2005) treated with 
radiation therapy.  
Case control studies have also been conducted demonstrating dose-response relationships 
between lung cancer and patients treated previously with IR for ankylosing spondylitis (Weiss, 
Darby, & Doll, 1994), peptic ulcers (Carr et al., 2002), female breast cancer (Inskip, Stovall, & 




environmental exposures to radon in a Colorado cohort of uranium miners was also shown to 
significantly elevate lung cancer risk, however the absolute risk increase was greater among 
smokers (Council, 1999; Lubin et al., 1995).  
All of these studies highlight the role of IR as a carcinogen in humans, as most solid 
cancers and leukemia have been found to be associated  with radiation exposure, however the 
most reliable risk estimations exists for leukemia, breast, lung, and thyroid (Gilbert, 2009). They 
also highlight the inherent risks associated with using radiation to treat cancer and non-cancer 
diseases as well as the need for a greater understanding of the biological and molecular processes 
involved in radiation carcinogenesis.  
 
Radiobiology in Radiation Therapy 
About half of those diagnosed with cancer in the United States receive radiation therapy 
as part of their treatment (Ballas, Elkin, Schrag, Minsky, & Bach, 2006). Radiation therapy is 
defined as the use of high energy photon or particle radiation to shrink tumors and kill cancer 
cells (Institute; Lawrence TS, 2008). Radiation therapy can be divided into external beam which 
includes the use of photons and charged particles and internal or brachytherapy which utilizes 
internal emitters or radioisotopes located near or absorbed by the tumor to produce therapeutic 
gains (Institute). In the United States, radiation therapy is dominated by the use of photon based 
modalities including external beam radiation therapy (EBRT), intensity modulated radiation 
therapy (IMRT), image guided radiation therapy (IMRT), tomotherapy, stereotactic radiosurgery 
(SRS), and stereotactic body radiation therapy (SBRT) which all utilize traditional 




Additionally, charged particle regimens including proton, electron, and carbon ion therapy are 
commonly used in the treatment of rare, radioresistant tumors (Institute).  
The overarching goal of radiation therapy is to generate tumor killing with either curative 
or palliative intent while also sparing normal, non-tumor tissues the detrimental effects of 
radiation exposure (Hall, 2006). Traditional radiation therapy is based in the principle of 
fractionation where the delivery of total radiation dose is divided into smaller (usually 2 Gy) 
fractions separated by time (usually one day). Fractionation maximizes the therapeutic gains 
from radiation therapy by killing the quickly dividing tumor cells and sparing the slowly dividing 
normal tissues thereby preventing unwanted side effects which limit the amount of radiation 
delivered to the tumor. It is now understood that the therapeutic gains from radiation 
fractionation arise due to the four R’s of radiation therapy which include reassortment, repair, 
reoxygenation, and repopulation (Hall, 2006).  
The first of these principles, reassortment, arises from differences in radiation sensitivity 
of cells at different points in the mitotic cell cycle. Specifically, cells in G1 and late S-phase are 
more radio resistant than those in other phases of the cell cycle (Hall, 2006). Conversely, cells in 
G2/M and early S-phase tend to be more radiosensitive. When a dividing cell population is 
exposed to radiation, those cells in more radiosensitive phases of the cell cycle are preferentially 
killed. This is an advantage to fractionated radiation therapy because in the time following a 
single dose, those cells which survive will progress (reassort) into less radio resistant phases of 
the cell cycle and the population will be more sensitive at the time the next radiation fraction is 
delivered. This is also beneficial to sparing of normal tissues and cells because they divide more 




Both normal and cancer cells have numerous pathways that repair the damage to DNA 
caused by IR. Due to this fact, much of the damage caused by IR can be referred to as sub-lethal 
damage (SLD), as it is unable to kill a cell assuming it gets repaired quickly and efficiently. SLD 
damage is the operational term for the increase in cell survival that is observed if a given 
radiation dose is split into two fractions separated by a time interval (Hall, 2006). SLD repair 
provides radio resistance to both tumor and normal cell populations under fractionated 
radiotherapy as the time between fractions allows for the SLD to be repaired (Hall, 2006). In the 
case of low dose rate radiation exposure, which can be thought of as the ultimate hyper-
fractionation scheme, repair can actually occur while IR exposure is taking place and result in 
decreased cell death (K. K. Fu, Phillips, Kane, & Smith, 1975). Work done by Elkind et al 
demonstrated SLD repair in a two fraction experiment in which two equal fractions of radiation 
were delivered to chinese hamster ovary cells (CHO) separated by time and maintained at room 
temperature to prevent movement through the cell cycle. Dividing the two fractions and waiting 
for 30 minutes between dose deliveries increased the overall survival of cells relative to a single 
acute dose. As the time interval between the two doses was increased, the surviving fraction 
increased and plateaued at around 2 hours between doses (Elkind, Sutton-Gilbert, Moses, 
Alescio, & Swain, 1965). In a parallel experiment where cells were maintained at their normal 
growing temperature, the pattern of survival was drastically different. If the second fraction was 
delivered in the first few hours after the first fraction, SLD repair was evident and mirrored the 
room temperature experiment, however survival fell dramatically at five hours between the two 
fractions, and increased dramatically thereafter (Elkind et al., 1965). This can be explained by 
reassortment, and cells entering more sensitive phases of the cell cycle following the first 




by dividing the total dose delivered into fractions, and allowing time between those fractions, 
cells are able to repair SLD and display increased cell survival. While this increases the survival 
of tumor cells, it also helps to minimize the effects of IR exposure on normal cells that may be in 
the radiation field.      
Oxygen has long been recognized as a potent radiation sensitizer as cells grown in the 
presence of oxygen are more sensitive to the effects of IR exposure than those under hypoxic 
conditions (Palcic & Skarsgard, 1984). The ratio of the difference in dose necessary to achieve 
the same biological effect with and without oxygen is known as the oxygen enhancement ratio 
(OER) (Hall, 2006). The OER is high for photons and lower for high LET particle radiation 
(Barendsen et al., 1966). In order for the OER to be observed, molecular oxygen must be present 
at the time of radiation exposure. The molecular basis for this phenomenon is described by the 
oxygen fixation hypothesis in which absorbed radiation generates free radicals that interact with 
DNA producing DNA radicals. In the presence of molecular oxygen, these DNA radicals can 
react with oxygen producing chemically un-restorable organic peroxides in the DNA (Barilla & 
Lokajicek, 2000; Ewing, 1998; Spiro, Ling, Stickler, & Gaskill, 1985). The OER is important to 
radiation therapy because solid tumors often have areas of poorly vascularized and therefore 
hypoxic, necrotic cores (Brown & Giaccia, 1998). The cancer cells residing in these necrotic 
regions are relatively radio resistant due to a decreased partial pressure of oxygen (Brown, 1979), 
thus large acute doses of radiation will selectively kill the well oxygenated tumor cells leaving 
the hypoxic tumor cells to divide. Fractionation serves to alleviate this problem by allowing the 
necrotic region of the tumor to reoxygenate in the time between radiation fractions as the tumor 




Treatment with cytotoxic agents such as IR or chemotherapy can trigger surviving cells 
(clonogens) in a tumor to divide more rapidly than before, a phenomenon known as accelerated 
repopulation (Hall, 2006; Withers, 1977; Withers, Taylor, & Maciejewski, 1988). A transplanted 
tumor model in rats first demonstrated accelerated repopulation when a single acute dose of 20 
Gy x-rays resulted in an initial decrease in tumor volume indicating regression; however the 
surviving clones divided more rapidly than prior to radiation treatment, effectively repopulating 
the tumor more quickly than it was growing prior to IR (Hermens & Barendsen, 1969). This is 
important because as the tumor was overtly shrinking, the surviving clones were dividing more 
rapidly than ever (Hall, 2006). A similar phenomenon was also reported in human head and neck 
cancers (Withers et al., 1988). In this study, Withers et al reported accelerated repopulation at 28 
days after the initiation of radiotherapy in a fractionated regiment. Furthermore they reported that 
an additional dose increment of about 0.6 Gy/day was necessary in order to account for this 
accelerated repopulation (Hall, 2006; Withers et al., 1988). Thus in the treatment of human 
tumors, the regimen should be completed as quickly as possible in order to avoid complications 
imposed by accelerated repopulation. While there is ample experimental evidence supporting the 
concept of accelerated tumor repopulation following radiotherapy, the molecular aspects and 
pathways involved remain poorly understood, although recent reports suggest an intricate 
balance in which signals from dead or apoptotic cells induce a wound healing response (Q. 
Huang et al., 2011). 
The goal of traditional, fractionated radiation therapy is to utilize the fundamental 
radiobiological principles described above in order to increase tumor killing while at the same 
time sparing normal tissues the detrimental effects of IR exposure, the definition of a therapeutic 




allowed for the creation of hypo-fractionated regimens in which much larger acute doses of IR 
are delivered specifically to the tumor while preferentially sparing normal tissues due to more 
accurate delivery of radiation dose. While effective, the underlying radiobiology and signaling 
pathways, in particular, those involving telomeres and telomerase associated with these new 
modalities including IMRT, SRS, SBRT, and heavy ion therapies remain poorly understood and 
represent research opportunities for improving radiotherapy. 
 
Telomeres and Ionizing Radiation  
 
Telomeres were first identified as functional structures in experiments using X-rays to 
fragment chromosomes in maize and drosophila (McClintock, 1938; Muller, 1938). In these 
experiments Mueller and McClintock noted that telomeres behave quite differently than the 
DSB’s induced by ionizing radiation. Telomeres are essential features for preventing 
chromosome ends from being recognized as damaged DNA, therefore telomere function is 
closely related to maintaining genomic stability (Silvestre & Londono-Vallejo, 2012).  
Telomeres can become dysfunctional either through excessive shortening (loss of sequence) or 
loss of end capping function (loss of structure) due to defects in the proteins that for or 
associated with the shelterin complex  (Frias, Pampalona, Genesca, & Tusell, 2012). Thus, 
multiple studies have been undertaken to investigate the link between telomere function and 
radiation sensitivity.  
Telomere shortening was shown to play a role in radiation sensitivity when mouse 
embryonic fibroblasts (MEFs) deficient in TERC and expressing critically short telomeres, 
exhibited symptoms reminiscent of radiation sensitivity syndromes, including decreased survival 
of MEF’s (K. K. Wong et al., 2000). Additionally, this radiosensitivity correlated with delayed 




widespread chromosomal fragmentation (Bailey & Cornforth, 2007). It has also been shown that 
short telomeres in telomerase knockout mice are also capable of fusing to the sites of radiation 
induced double strand breaks (Genesca et al., 2006; Latre et al., 2003). In humans, it has been 
noted that short telomeres were predictive of increase chromosomal instability following 
treatment of patients with Hodgkin’s lymphoma (M'Kacher et al., 2007). Such findings suggest a 
strong association between shortened telomeres and radiation induced genomic instability and 
provide a potential explanation for why radiosensitivity increases with age. 
A second manner by which telomeres can become dysfunctional results from loss of 
telomere end-capping function (Bailey & Cornforth, 2007), which can occur due to loss of 
function of various proteins known to play a critical role at telomeres. In addition to proteins of 
the shelterin complex, this list also includes proteins associated with the repair of IR induced 
double strand breaks via non-homologous end joining (NHEJ) and includes the DNA dependent 
protein kinase (DNA-PK) holoenzyme comprised of the Ku70/Ku80 heterodimer and the DNA-
PK catalytic subunit (DNA-PKcs) (Iliakis et al., 2004; Jeggo, 1998). Cells deficient in DNA-
PKcs demonstrate hyper radiosensitivity and cancer susceptibility (Auckley et al., 2001; 
Ponnaiya, Cornforth, & Ullrich, 1997; Someya et al., 2006). Bailey et al demonstrated that loss 
of function of DNA-PKcs resulted in reduced telomeric end-capping function and the formation 
of telomere-telomere and telomere-DSB fusion events in the absence critical telomere shortening 
(Bailey, Brenneman, et al., 2004; Bailey, Cornforth, Ullrich, & Goodwin, 2004; Bailey et al., 
1999). Since DNA-PKcs mutations are known to occur in humans, this is of particular 
importance to radioprotection and carcinogenesis.  
In addition to the roles mentioned above, IR and oxidative stress have also been shown to 




Mondello, 2008) and loss of telomere function has been implicated as a major driver of 
carcinogenesis (Ayouaz, Raynaud, Heride, Revaud, & Sabatier, 2008). Thus it becomes 
abundantly clear that telomeres are not only contributors to radiation sensitivity and survival, but 
with their intimate link to DSB repair, telomeres are also important drivers of carcinogenesis.     
 
Telomerase and Ionizing Radiation  
Human telomerase plays a vital role in embryonic development and the maintenance of 
the adult stem cell niche (Flores & Blasco, 2010). hTERT is repressed in the majority of adult 
somatic cells, being reactivated during the development of most cancers and so classification as 
an oncogene (Daniel, Peek, & Tollefsbol, 2012). Recent findings, including connections to the 
Wnt/β-catenin and NF-κB (Chung, Aroh, & Vadgama, 2013) signaling pathways and links to 
angiogenesis (Falchetti et al., 2008), have led to the hypothesis that telomerase not only regulates 
cellular lifespan, but is central to all the hallmarks of cancer (Low & Tergaonkar, 2013). This 
body of work has led us to speculate that telomerase plays critical roles in radiation 
carcinogenesis and accelerated tumor repopulation following radiation therapy. 
In the late 1990’s, it was demonstrated by multiple groups that telomerase activity is 
elevated by ionizing radiation in cancer and can be used to assess the radio curability of tumor 
cells (Finnon, Silver, & Bouffler, 2000; Hyeon Joo, Hande, Lansdorp, & Natarajan, 1998; 
Karimi-Busheri, Rasouli-Nia, Mackey, & Weinfeld, 2010; Leteurtre, Li, Gluckman, & Carosella, 
1997; Neuhof, Ruess, Wenz, & Weber, 2001; Ogawa et al., 1998; Pandita & Roti Roti, 2003; 
Perez Mdel et al., 2002; Sawant et al., 1999; Terashima et al., 1998; X. Wang et al., 2000; P. 
Zhao, Li, Yang, & Wang, 1999). In one study, HeLa cells exposed to therapeutically relevant, 




persisted up to 5 days post IR exposure (Sawant et al., 1999). The traditional explanation for this 
phenomenon was that telomerase is played a role in DNA repair (Leteurtre et al., 1997). 
However, Elkind et al (Elkind & Sutton, 2012) demonstrated that most of the damage induced by 
IR was repaired within the first 4-12 hours following exposure, leading to the question of why 
telomerase remains activated. Additionally, in-vivo assessment of relapsed tumors also showed 
elevated telomerase activity relative to cured tumor controls, providing further evidence that 
telomerase may be playing a role in accelerated repopulation of tumors (Sawant et al., 1999).   
Furthermore, findings of increased telomerase activity have been observed in other model 
systems including MCF-7 mammary carcinoma cells (Karimi-Busheri et al., 2010), KG1a AML 
cells (Perez Mdel et al., 2002), colon carcinoma (Hyeon Joo et al., 1998), squamous cell 
carcinomas of the oral cavity (Abe et al., 2008), lymphoma and myeloma (Terashima et al., 
1998), chronic human skin ulcers related to skin cancer (P. Zhao et al., 1999), murine leukemia 
(Finnon et al., 2000), nasopharyngeal carcinoma (X. Wang et al., 2000), and immortalized 
human lymphoblast cells (Neuhof et al., 2001). While each of these studies suggested that 
telomerase activity was elevated following IR exposure, the doses necessary to induce the 
elevation, the time telomerase remained elevated post exposure to IR, and the degree of elevation 
was wildly inconsistent. Furthermore, little work was done to assess the response of telomerase 
activity in normal human cells, following low dose rate IR exposure, or for periods longer than 3 
days, or to explain what was causing the changes in telomerase activity. Therefore, the studies 
reported here seek to assess the mechanisms of telomerase activation following IR exposure in 
both normal and cancer cell lines exposed to varying doses of both high and low dose rate IR.  






Radiation induced Stem Cell Enrichment in Cancer and Normal Tissues 
 
Cancer Stem Cells in the Treatment of Cancer 
 
Like ESCs, cancer stem cells can self-renew and have pluripotent capacity. CSCs are 
thought to be the basis for tumor initiation, development, metastasis, and recurrence of cancer 
following therapy (Chen, Huang, & Chen, 2013). The concept was first acknowledged in 1963 
when it was determined that only 1-4% of lymphoma cells were able to form colonies in vitro or 
initiate carcinoma in mouse spleen (Bruce & Van Der Gaag, 1963). However it was not until 




 subpopulation of human AML cells could initiate 
malignancy in immunodeficient mice that strong evidence for the theory emerged (Bonnet & 





 breast tumor cells contained the CSC characteristics similar to those 
found in AML (Al-Hajj, Wicha, Benito-Hernandez, Morrison, & Clarke, 2003). Currently, CSC 
populations have been identified in nearly all solid tumors including lung, colon, prostate, 
ovarian, brain, melanoma, and osteosarcoma (Chen et al., 2013). A list of the markers used to 
identify CSCs in various tumors can be found in table 1.  
Cancer stem cells are thought to be one of the predominant factors leading to failure of 
current therapeutic strategies, as they are thought to be the drivers of resistance to both radiation 
and chemotherapy (LaBarge, 2010; Lacerda, Pusztai, & Woodward, 2010; Z. Wang, Y. Li, et al., 
2010). Due to this fact it is necessary to target and eliminate the CSC population in order to 
improve treatment outcome, however most conventional therapies do not adequately eliminate 







Cellular Plasticity and Somatic Cell Reprogramming  
 
Potency and self-renewal are the defining characteristics of stem cells, however 
experiments conducted within the last decade have given rise to the question of whether 
“stemness” refers to a specific cell population or a cell property (Antoniou, Hebrant, Dom, 
Dumont, & Maenhaut, 2013). Traditionally, cell fate was thought to be irreversible; meaning that 
once a cell has committed to a lineage it cannot be reversed. However, the induction of 
pluripotency was demonstrated in differentiated mouse (Yamanaka & Takahashi, 2006) and later 
human (Takahashi et al., 2007; Zaehres & Scholer, 2007) fibroblasts through the introduction of 
transcriptional reprogramming  factors, effectively reversing the committed lineage and reverting 
these cells to more primitive ESC-like states of pluripotency. This feature of cell fate is now 
referred to as “plasticity” and the process by which it occurs is termed “reprogramming” 
(Elshamy & Duhe, 2013). 
Reprogramming has been demonstrated in several experimental models. Direct 
reprogramming to pluripotency can occur through introduction of transcription factors octamer  
binding transcription factor 4 (Oct4), krupple like factor 4 (Klf4), sex determining region Y box 
2 (Sox2), and cMyc (Yamanaka & Takahashi, 2006). Such induced pluripotent stem cells 
(iPSCs) can then be cultured under appropriate conditions to differentiate into any specialized 
cell type. Additionally, it was recently demonstrated that differentiated cells of one type can be 
directly reprogrammed into cells of another differentiated cell type without first proceeding 
through a pluripotent state through the forced expression of two or three transcription factors 
(Efe et al., 2011; Ieda et al., 2010; J. Kim et al., 2011).  
Reprogramming can also occur through the process of somatic cell nuclear transfer 




cell was transferred to the cytoplasm of an enucleated egg, resulting in the development of a 
genetically identical adult frog (Gurdon, Elsdale, & Fischberg, 1958). SCNT proved that the 
nucleus of a somatic cell contains all the information necessary and sufficient to make another 
organism, and that it can be reprogrammed by factors present in the egg cytoplasm. This same 
process was used to clone the famous sheep “Dolly” in 1997 (Wilmut, Schnieke, McWhir, Kind, 
& Campbell, 1997), and has been demonstrated in human cells as recently as 2013 (Tachibana et 
al., 2013).   
Finally, reprogramming can occur due to changes in environmental signaling, first 
demonstrated in 1998 when the bone marrow of normal adult mice was transferred into the 
skeletal muscle of different adult mice. The transplanted bone marrow was able to form new 
muscle fiber nuclei indicating that the microenvironment of the skeletal muscle exerted a 
reprogramming effect on the bone marrow cells, effectively turning them into skeletal muscle   
(Ferrari 1999). Thus, transplanting adult cells from one tissue type into another may give rise to 
one or more cell types that are typical of the recipient environment. The predominant thought is 
that extracellular signaling molecules in the cellular microenvironment help to dictate cell fate 
and changing that microenvironment induces reprogramming or conversion (not necessarily 
through a pluripotent state).  Thus, plasticity can be thought of as the ability of a cell to change 
its phenotype in response to extra-cellular signals, however, this ignores the “trans-differential” 
aspects presented by PSC induction and SCNT. 
The concept of cellular plasticity has led several groups to propose rethinking of the 
rigid, unidirectional, hierarchal model of cellular differentiation in normal epithelial and 
mesenchymal tissues and cancer in favor of a bidirectional, phenotypic equilibrium model in 




(Elshamy & Duhe, 2013; Gupta et al., 2011). It also provides potential new (and perhaps 
universal) targets in the effort to treat cancer as this interconversion between cell types has been 
linked to carcinogenesis, tumor progression, metastasis, and recurrence following therapy.  
The epithelial to mesenchymal transition (EMT) and the reverse process of mesenchymal 
to epithelial transition (MET) are common phenomenon occurring during embryogenesis that aid 
in the differentiation of specific gestational layers to form the organs of the human body (Nakaya 
& Sheng, 2013). Both of these transitions are intimately connected to cancer progression and 
may provide the driving force for metastasis (Elshamy & Duhe, 2013), as they are processes of 
cellular reprogramming and play important roles in cancer. Cancer cells undergoing EMT are 
capable of surviving genotoxic stress and are resistant to both chemo- and radiation therapy 
(Fillmore & Kuperwasser, 2008). Additionally, it has been demonstrated on numerous occasions 
that invasive, metastatic cells also undergo EMT (Du et al., 2011). While undergoing EMT, 
breast carcinoma cells often acquire stem like properties including increases in CD44 levels as 
well as decreases in CD24 levels (Louie et al., 2010; Mani et al., 2008) indicating an increase in 
the number of CSCs.  
Together, these findings suggest that phenotypically, cancer stem cells, reprogrammed 
non-stem cancer cells, those cells undergoing EMT, and metastatic cells are all essentially the 
same, indicating that cellular plasticity not only drives tumor development and metastasis, but 
may also prevent therapies targeting CSC’s from proving effective for the treatment of cancer.     
 
Radiation Induced Enrichment of Cancer Stem Cells  
 
The qualities of CSCs concerning to cancer treatment include resistance to radiation and 




processes involved in the maintenance or generation of previously non-existing (reprogrammed) 
CSCs contribute to cancer development, therefore therapy induced second cancers, and tumor 
recurrence. This assumption is confirmed by the fact that biomarkers for CSCs are indicative of 
poor treatment outcome and the inactivation of CSCs within a tumor determines permanent local 
control (Butof, Dubrovska, & Baumann, 2013). Therefore it can be assumed that any process that 
increases the number of CSCs within a tumor could potentially lead to a poor clinical outcome.  
CSC enrichment is pertinent to radiation therapy, as it was demonstrated in 2006 
(Lagadec, Vlashi, Della Donna, Dekmezian, & Pajonk, 2012; Lagadec et al., 2010; Phillips, 
McBride, & Pajonk, 2006) that exposure to therapeutic doses of X-rays significantly increased 




  breast cancer stem cells in culture. Furthermore other groups 
have demonstrated a similar stem cell enrichment of colorectal and breast CSCs following 
exposure to therapeutically relevant doses of γ-rays (Cui et al., 2011; Yang et al., 2012). 
Interestingly, significant increases in CSCs populations were not observed following equivalent 
doses of carbon ion therapy, indicating that radiation quality may play a role (Cui et al., 2011). 
Together, these findings suggest that one reason for tumor relapse and secondary cancers 
following radiation therapy may be due to an enrichment of CSCs that are inherently more radio 
resistant, have a larger capacity for cell division, and are more invasive than NSCCs therefore 
contributing to accelerated repopulation.  
The original explanation for the enrichment of CSC following radiation therapy was that 
existing CSCs within the tumor at the time of dose delivery were more radiation resistant than 
their NSCC counterparts and therefore were more likely to survive fractionated radiation 
therapy. Such a scenario implies that CSC enrichment is due to the selection, mobilization, and 




interconversion (reprogramming) of NSCC’s into CSCs and that radiation encourages this 
process (Lagadec et al., 2012; Yang et al., 2012). Even more intriguingly, Yang et al. 
demonstrated that CSCs spontaneously convert to NSCC and vice versa even without radiation 
exposure to maintain an equilibrium population of CSCs, and that exposure to radiation 
accelerated the rate of interconversion back to equilibrium (Yang et al., 2012). Therefore, tumors 
not only rely on CSCs to propagate, but they also have a mechanism to maintain a stochastic 
equilibrium percentage of CSCs.  
While selection and reprogramming are two different paths leading to enrichment of 
CSCs, it is likely that within a tumor, both processes play a role in CSC enrichment and therefore 
tumor repopulation. These findings suggest that in order to improve radiation therapy, a 
combination of cell killing achieved through maximizing the delivered dose, targeting and 
eliminating existing CSCs, and preventing the conversion of NSCCs into CSCs via 
reprogramming must be achieved. 
          
Conclusions 
 
Our goal in the present studies was to characterize the response of telomeres and 
telomerase to ionizing radiation in a panel of normal, non-cancer immortalized, and cancer cell 
lines. We first sought to verify elevations of telomerase activity in cancer cell lines following IR 
exposure and to determine whether those elevations correlated with changes in hTERT and 
hTERC expression and protein levels. We then expanded these studies to examine changes in 
telomerase activity in primary and non-tumorigenic immortalized cell lines of mammary and 
hematopoietic origin, as well as to prolonged low dose rate (LDR) exposures and telomere length 




24-48 hours post exposure in mammary carcinoma and AML cell lines, but not in non-
tumorigenic and primary cell lines. These findings suggest that the deregulation of telomerase 
that occurs during carcinogenesis plays a distinct role in the survival and repopulation of human 
cancer cell lines exposed to IR, however checkpoint activation may prevent telomerase from 
acting in the same way in non-tumorigenic and primary cell lines. Furthermore, as changes in 
telomerase activity did not track with increases in telomere length, we can conclude that 
telomerase is acting outside of its canonical role in telomere elongation.  
We next sought to elucidate the mechanisms leading to increases in telomerase activity. 
We hypothesized that since stem cells (and CSCs) have a higher background telomerase activity 
relative to their non-stem (and NSCC) counterparts that stem cell enrichment following IR 
exposure may correlate with increases in telomerase activity. Our results however suggest that 
elevation in telomerase activity precedes stem cell enrichment and that there is no association 
between the percentage of stem cells in a culture and telomerase activity. To determine if 
telomerase is necessary for the radiation induced enrichment of stem cells, we applied a 
combined small molecule inhibitor and RNA interference (RNAi) approach. Our results suggest 
that the reverse transcriptase activity of telomerase is necessary for radiation induced stem cell 
enrichment.  
Taken together, these findings demonstrate a critical role of telomerase in the survival 
and repopulation of tumors following radiation therapy which may be independent of its 
canonical reverse transcriptase function. Our results also suggest a potential role for combined 
radiation and anti-telomerase therapy to produce higher rates of recurrence free survival as well 




tissues. Future studies will seek to discover additional telomere based therapies which could be 






Figure 1.1: Schematic of the T-loop structure. TRF1, TRF2, and POT1 (not shown) bind directly 
to the telomere sequence. Proteins associated with double strand break repair pathways also 
interact with the telomere through protein-protein interactions with shelterin. The 3’ single 
stranded overhang binds the DNA duplex displacing the upstream DNA duplex to form a 







Figure 1.2: Telomere shortening in normal tissue aging and carcinogenesis.  In normal human 
somatic tissues, telomeres shorten by 30-100 base pairs per cell division, a process that 
eventually leads to telomere based growth arrest/senescence. Adult stem cells and germ line cells 
maintain telomere length through the activity of telomerase. Human tumors must overcome 
telomere based growth arrest and accomplish this through reactivation of telomerase or the 
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Telomerase, the reverse transcriptase that serves to maintain telomere length, is a critical 
player regulating the proliferative lifespan of human cells. Reactivation of telomerase is a critical 
rate limiting step in the process of carcinogenesis as well. Interestingly, increased telomerase 
activity has also been linked to accelerated tumor repopulation following radiation therapy and 
so may provide a critical target for improving therapeutic intervention strategies. We 
hypothesized that telomerase activity would be elevated in normal and non-cancer cell lines as 
well as cancer cell lines following IR exposure. To more clearly elucidate the effects of ionizing 
radiation (IR) exposure on telomerase activity, we tracked changes in telomerase, expression of 
telomerase components hTERT and hTERC, and telomere length in a panel of human cancer and 
non-cancer cell lines following acute and low dose rate (LDR) IR exposures. Elevation of 
telomerase activity following acute IR exposure was observed specifically in cancer cells, while 
LDR exposure decreased rather than increased telomerase activity. Furthermore, and to the best 
of our knowledge, we are the first group to report significant telomere shortening across all the 
individual telomeres examined in dividing cell populations as a result of acute IR exposure. 
These findings indicate that the interplay between telomeres, telomerase, carcinogenesis, and IR 
exposure are complex and highlight the need for studies that increase our understanding of the 







Telomerase is expressed at high levels in the majority of human tumors, facilitating 
cellular immortalization and evasion of cellular senescence (Shay & Wright, 2011). Normal adult 
somatic cells do not have telomerase activity with the exception of rare adult, multipotent stem 
cell (ASC) populations which repopulate and heal tissues following injury (Flores & Blasco, 
2010). Telomerase activity in ASCs conveys an extended replicative lifespan and the ability to 
self-renew through symmetric and asymmetric cell division (Armanios & Greider, 2005). 
Activation of telomerase is a critical, early step in the process of carcinogenesis leading to its 
classification as an oncogene (Low & Tergaonkar, 2013).  
Ionizing radiation (IR) is a potent carcinogen linked to the development of a variety of 
solid and blood cancers, most notably breast cancer and leukemia (Gilbert, 2009). Interestingly, 
it has been demonstrated that acute γ- and x-ray exposures induce increased telomerase activity 
in human tumors and cell lines including mammary carcinoma (Karimi-Busheri et al., 2010), 
acute myeloid leukemia (AML) (Leteurtre et al., 1997; Perez Mdel et al., 2002), colon carcinoma 
(Hyeon Joo et al., 1998), squamous cell carcinoma of the oral cavity (Y. Ogawa et al., 1998), and 
lymphoma (Terashima et al., 1998) for up to 5 days post IR exposure. This increase in 
telomerase activity has been linked to accelerated repopulation of tumors following radiation 
therapy, and so may represent a potent target to increase the clinical efficacy of radiation therapy 
(Pandita & Roti Roti, 2003; Sawant et al., 1999). Increased telomerase activity following IR has 
generally been regarded as evidence of telomerase activity in DNA repair. However, considering 
that most of the damage resulting from IR exposure is repaired within the first 2-12 hours 
following exposure (Elkind et al., 1965), we thought it unlikely that telomerase is functioning 




While the effects of IR exposure on telomerase activity are well studied in tumors and 
cancer cell lines, little has been done to evaluate the effects of IR on telomerase in normal 
(telomerase negative) and non-tumorigenic (telomerase positive, but not deregulated) cell lines. 
IR may well induce changes in telomerase activity in these cells potentially increasing their 
cellular lifespan. Because telomerase activity was elevated in cancer cell lines, we hypothesized 
that acute IR exposure would activate telomerase in normal and non-tumorigenic immortalized 
cell lines, and thereby contribute to cellular immortalization and carcinogenesis.  
To test this hypothesis we selected a panel of normal, non-tumor immortalized, and 
cancer cell lines of mammary epithelial and hematopoietic origin, exposed them to acute doses 
of ionizing radiation, and tracked changes in telomerase activity utilizing the quantitative real 
time polymerase chain reaction  (q-RT PCR) based telomere repeat amplification protocol 
(TRAP) (Herbert, Hochreiter, Wright, & Shay, 2006). In our mammary epithelial cell panel, we 
further examined hTERT and hTERC expression levels in response to IR.  We also tracked 
changes in telomerase activity following equivalent doses of chronic low dose rate (LDR) IR 
exposure to determine if changes in telomerase activity exhibit a dose rate effect. Additionally, to 
assess whether changes in telomerase activity had an associated effect on telomere length, we 
tracked changes in telomere length using quantitative fluorescence in situ hybridization (Q-
FISH) (Poon & Lansdorp, 2001).  
Our results, in agreement with the published literature, indicate that telomerase activity is 
elevated in cancer cell lines 24-48 hours post exposure to various doses of IR, and corresponds to 
changes in hTERT mRNA expression levels. No noticeable increase in telomerase activity in 
normal or non-cancer cell lines was observed. Additionally, telomeres shortened (~20-30%) in 








The human mammary epithelial non-tumorigenic cell line MCF-10a was purchased from 
ATCC and was cultured as described previously (Le, Maranon, Altina, Battaglia, & Bailey, 
2013) in 1:1 Dulbecco’s Modified Essential Medium (D-MEM)/Ham’s F12 growth medium 
(Hyclone) supplemented with 5% fetal bovine serum (FBS), 10 µg/mL insulin (Sigma), 20 
ng/mL epidermal growth factor (EGF; Sigma), 0.5 µg/mL hydrocortisone (Sigma), 0.1 µg/mL 
cholera toxin (Sigma), and 1% glutamax (Life Technologies). The human mammary carcinoma 
cell line MCF-7 (kind gift from L. Chubb, CSU Animal Cancer Center) was grown in D-MEM 
supplemented with 10% FBS and 1% glutamax. The primary mammary epithelial cell line 
AG11137 (Coriell) was grown in MCDB 170 complete growth medium (US biological) 
supplemented with 5 µg/mL insulin, 10 ng/mL EGF, 0.5 µg/mL hydrocortisone, 56 µg/mL 
bovine pituitary extract (Life Technologies), and 1% glutamax. 
A human primary immortalized, low passage lymphoblast cell line (LCL15044 kind gift 
from A. Sigurdsson, National Institute of Health) was grown in RPMI medium supplemented 
with 15% FBS and 1% glutamax. The WTK1 immortalized lymphoblast cell line (kind gift from 
H. Liber, Colorado State University) was grown in RPMI medium supplemented with 10% fetal 
horse serum and 1% glutamax. Human acute myeloid leukemia cells KG1a (Kind gift from 
Michelle LeBeau, University of Chicago) were grown in RPMI media supplemented 20% FBS 
and 1% Glutamax. The human osteosarcoma ALT cell lines U2OS and SAOS2 (kind gift from 
D. Gustafson Colorado State  University Animal Cancer Center) were grown in McCoy’s 5A 
growth medium (Life Technologies) supplemented with 10% FBS and 1% glutamax. Primary 




Medical School) and hTERT immortalized primary human fibroblasts (BJ1 hTERT) (kind gift 
from J. Bedford, Colorado State University) were grown in a 4:1 mixture of D-MEM high 
glucose medium (Hyclone) / M-199 (Hyclone) supplemented with 10% FBS and 1% glutamax. 
All cells were grown at in a humidified incubator at 37
O





Cells were exposed to various, acute doses of 
137
Cs γ-rays in a Mark I irradiator (J.L. 
Shepherd) located at Colorado State University. Cells were exposed at a dose rate of 2.5 Gy/min 
with rotation. For LDR exposure, cells were incubated under a 
137
Cs source for total doses of 1 
or 4 Gy of γ-rays at dose rates of 4.9 and 3.12cGy/hour. Un-irradiated controls were kept in a 
separate incubator under identical conditions.  
 
Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) Telomere Repeat Amplification 
Protocol (TRAP) 
 
Telomerase activity was detected via the telomere repeat amplification protocol (TRAP) 
assay originally described by Herbert (Herbert et al., 2006) et al and adapted for real time PCR 
by Hou et al (Hou, Xu, Bjorkholm, & Gruber, 2001). Briefly, whole cell lysates were prepared 
from cultured cell pellets, lysed in cold MPER mammalian protein extraction buffer (Thermo 
Fischer) containing a protease inhibitor cocktail (Roche) and RNasin ribonuclease inhibitor 
(Promega) at a ratio of 100 µl of buffer per 1,000,000 cells. Lysates were cleared by 
centrifugation at 14,000 RPM for 10 minutes at 4
o
C, aloiquotted, and stored at -80
o
C. Protein 
concentration was determined using the Bradford Assay (Biorad).   
The SYBR green master mix (Promega) included all necessary components to complete 




volume of SYBR green master mix, 0.2µg T4 gene32 protein (New England Biolabs, Ipswitch, 
MA), 0.1µg of each primer TS (5’-AATCCGTCGAGCAGAGTT- 3’) and ACX (5’-
GCGCGG(CTTACC)3CTAACC-3’) (Integrated DNA Technologies) and RNase/DNase free 
water to achieve a final well volume of 25ul. The PCR and detection were performed on a CFX 
96 (Biorad). In addition to the treatment samples, a series of controls were also included on each 
plate: (1) no template control with TS primer only, (2) no template control with ACX primer 
only, (3) no template control with TS and ACX primers (used in normalization of samples), (4) 
heat inactivated control with template (protein lysate) and TS and ACX primers, (5) HeLa cell 
lysate with TS and ACX primers (a positive control with robust telomerase activity).  
The RTQ-PCR program includes the following steps: Step 1- 1cycle 25℃ 20 min 
(telomerase elongates the TS primer by adding TTAGGG repeat sequences); Step 2- 1cycle 95℃ 
3 min (heat activation of the enzyme in the SYBR master mix); Step 3- 40 cycles of 95℃ for 20 
sec, 50℃ for 30 sec and 72℃ for 1min 30 sec (PCR amplification allows for detection by real 
time instrument); Step 4- 80 cycles 0.10 sec per cycle (melt curve to  ensures no primer dimer 
formation). Each sample is run in triplicate on a 96 well plate format allowing for an average Ct 
to be obtained per sample. Utilizing the average Ct value, the relative percent telomerase activity 
in each sample is calculated using the Delta Delta Ct method (2
-ΔΔCT
) (Livak & Schmittgen, 
2001). Briefly, to calculate the percent relative activity for each sample first normalize the 
average sample Ct to the no template control with TS and ACX primers. This is referred to as the 
delta Ct value. The delta Ct value of each sample is subtracted from the delta Ct value of a 
chosen comparative sample, in this case a normal feline mucous membrane cell lysate, yielding a 
delta delta Ct value (∆∆Ct). Using the 2
-ΔΔCT
, a relative value is generated for each sample 




the sample compared to the normal feline mucous membrane. The RTA can be compared 
between samples assayed across different plates. Results from two runs were averaged.  
 
Reverse Transcriptase PCR to Assess Changes in hTERT and hTERC Expression Levels 
 
Total RNA was harvested from irradiated and un-irradiated samples using the Qiagen 
RNeasy kit (Qiagen). RNA was quantified using a Nanodrop 1000 spectrophotometer and 
reverse transcribed using the Verso cDNA kit (Thermo Scienfitic). Real-time PCR was 
performed using SYBR green master mix (Promega) according to the manufactures protocol and 
performed using a CFX 96 system (Biorad). The real time cycle was as follows: Cycle 1 at 95
O
C 
for 15 minutes, cycle 2 (50X) step 1 at 95
O
C for 15 seconds, step 2 at 58
O
C for 30 seconds, step 
3 at 72
O
C for 30 seconds. A melt curve was included to assess for primer dimers and non-
specific amplification as follows: cycle 3 at 95
O
C for 30 seconds, cycle 4 at 55
O
C for 30 seconds 
and cycle 5 (80X) at 55
O
C for 10 seconds. Primers were designed using the Primer3 program 
(Rozen, 1998) using a published cDNA library for hTERT ((NCBI)) and hTERC ((NCBI)). 
hTERT primers were added at a final concentration of 300 nM including a forward sequence: 
CCATCAGAGCCAGCTTCACCT and reverse sequence: TCACCTGCAAATCCAGAAACA. 
hTERC primer were added at a final concentration of 300 nM including a forward sequence: 
AAGAGTTGGGCTCTGTCAGC and reverse sequence: TCCCACAGCTCAGGGAATC. 
Primers for transferrin receptor (TFRC) at a final concentration of 100 nM were included as a 
housekeeping gene with the forward sequence: CGCTGGTCAGTTCGTGATTA and the reverse 
sequence: GCATTCCCGAAATCTGTTGT. Relative hTERT and hTERC RNA expression were 
analyzed using the 2
-ΔΔCT






Telomere Length Analysis via Interphase Quantitative Fluorescence in situ Hybridization (FISH) 
 
Samples were prepared for interphase telomere length analysis using standard cytogenetic 
techniques as described previously with slight modifications (Le et al., 2013; Ourliac-Garnier & 
Londono-Vallejo, 2011; Poon & Lansdorp, 2001). Briefly, cultured cell pellets were resuspended 
in 8 mL of 75 mM potassium chloride (KCl; hypotonic) and incubated for 30 min at 37
O
C. 
Following incubation, 1 mL of fixative (3:1 methanol acetic acid) was added, cells were pelleted 
at 1000 RPM for 5 minutes, resuspended in 6 mL fixative, and stored at -20
o
C. Fixed cell pellets 
were then washed and dropped onto glass slides for telomere FISH analysis. Telomere FISH was 
performed as described previously with modifications (Dregalla et al., 2010).  
For telomere fluorescence in situ hybridization (FISH), slides were treated with 100ug/ml 
RNASE A in 150mM NaCl, 15mM Sodium Citrate buffer for 30 minutes at 37
O
C, dehydrated 
through an ethanol series (75%, 85%, and 100%), and denatured in a 70% formamide/2X saline 
sodium citrate (SSC) solution at 70
O
C for 2 minutes. A G-rich telomere peptide nucleic acid 
(PNA) probe (TTAGGG)3 labeled with Cy-3 was subsequently hybridized onto the slides at 
37
O
C overnight. Slides were washed twice each in 50% formamide/2X SSC, 2X SSC, and 0.1% 
NP-40 in 2X SSC for 2.5 minutes each at 43
O
C. Finally slides were mounted in Prolong Gold 
Antifade reagent (Invitrogen) with 4’,6-diamidino-2-phenylindole, dihydrochloride (DAPI). 
Image Z stacks were taken using a Zeiss Axio Imager.Z2 microscope, with a Coolsnap 
ES2 camera running Metamorph 7.7 (Molecular Devices). For each slide between 30 and 50 
images were obtained, each consisting of 22, 0.2um stacks. Metamorph nearest neighbor 
deconvolution and stack compression functions were then applied followed by image 




a region of interest was created for each nucleus and the intensities of individual telomeres were 
obtained in metamorph. 
Flourescence values obtained in each batch of FISH were standardized to the 
fluorescence intensity of an LY-R mouse lymphoma cell pellet as an internal control. LY-R cells 
have long brightly staining telomeres and their use for standardization, which was adapted from 
Q-FISH (H. P. Wong & Slijepcevic, 2004), represents a way to accurately compare relative 
telomere lengths from run to run.  
 
Statistical Analyses 
 Statistical differences were detected using a Student’s t-test against relevant controls. 
Statistical analysis was conducted using the Graph Pad Prism 5 software for windows XP.  
 
Results 
Telomerase Activity in Normal and Cancer Human Cell Lines 
To evaluate the sensitivity of the real time PCR based TRAP assay, we first compared 
telomerase activity across a panel of normal, non-tumor immortalized, and cancer human cell 
lines (Figure 2.1) that had been previously reported to express varying levels of telomerase 
activity (Karimi-Busheri et al., 2010; Kim et al., 1994; Sawant et al., 1999). HeLa cell lysates 
were utilized as a positive control and all values are reported as fold activity changes relative to 
HeLa cells. Consistent with published reports, cancer cell lines KG1a and MCF-7 had telomerase 
activity levels at 3.09 and 0.615 fold differences of HeLa cells respectively, indicating relatively 




heterozygous cell line (Neuhof, Ruess, Wenz, & Weber, 2001), had telomerase activity levels at 
a very high 12.83 fold increase compared HeLa cells (Figure 2.1 left panel).        
For comparison, the non-tumor immortalized cell lines BJ1 hTERT cells, which were 
transfected to express the telomerase hTERT component, the spontaneously immortalized 
mammary epithelial cell line MCF-10a, and the EBV immortalized low passage lymphoblast cell 
line LCL15044 displayed telomerase activity levels of 0.278, 0.0424, 0.0412 the activity of HeLa 
cells, indicating telomerase activity expression but at lower levels than those of comparable 
cancer cell lines (Figure 2.1 left panel). The normal human fibroblast cell line BJ1, primary 
mammary epithelial cells AG11137, and osteosarcoma cell lines U2OS and SAOS2 that 
maintain telomere length through the telomerase independent ALT pathway, all displayed 
telomerase levels at less than 0.035 fold of HeLa cells. Data on telomerase low and negative cell 
lines can be observed in the right panel of figure 2.1, which omits the inclusion of WTK1 and 
KG1a cell line telomerase activity to better accentuate the differences in telomerase activity in 
non-tumorigenic immortalized and normal cell lines (Figure 2.1 right panel). Based on these 
findings, it can be concluded that any cell line with less than about 0.04 fold the activity of HeLa 
cells is functionally telomerase negative using this assay. In addition, differences in telomerase 
activity were confirmed across numerous orders of magnitude, indicating extreme sensitivity 
over very large range of detection. 
 
Telomerase Activity in Cell Lines Exposed to Acute IR 
Numerous reports have demonstrated that IR induces elevation of telomerase activity in 
cancer cell lines for up to several days post exposure (Falchetti et al., 2008; Finnon, Silver, & 




Ogawa et al., 1998; Pandita & Roti Roti, 2003; Perez Mdel et al., 2002; Sawant et al., 1999; 
Terashima et al., 1998; Wang et al., 2000; Zhao, Li, Yang, & Wang, 1999). These reports have 
suggested that elevation of telomerase activity may play a role in accelerated tumor repopulation 
following radiation therapy, as well as contribute to the overall survival of cancer cells exposed 
to IR (Pandita & Roti Roti, 2003; Sawant et al., 1999). Despite numerous reports of telomerase 
activity being induced by IR in cancer, none have been conducted examining telomerase activity 
following IR exposure in non-cancer cell lines. We hypothesized that IR exposure would also 
elevate telomerase activity in non-tumor cell lines, and thereby contribute to IR induced 
carcinogenesis by prolonging the proliferative lifespan of cells carrying oncogenic mutations 
resulting from IR exposure (Shay & Wright, 2011).    
To verify these findings and to expand upon previous reports by examining changes of 
telomerase activity following IR exposure in non-tumor immortalized and normal cell lines, we 
tracked changes in telomerase activity as a factor of time at 24 hour intervals for up to 240 hours 
post-acute exposure to 10 Gy γ-rays in mammary epithelial cells MCF-7, MCF-10a, and 
AG11137. We also tracked changes in telomerase activity in hematopoietic cell lines KG1a, 
WTK1, and LCL15044 post-acute exposure to 1 and 4 Gy γ-rays up to 72 hours post exposure. 
All data are reported as values relative to un-irradiated (0 Gy) control samples within the same 
cell line.  
Our results demonstrate significant elevation of telomerase activity in MCF-7 
adenocarcinoma cells for up to 48 hours post IR exposure. This significant elevation returns to 
background levels by 72 hours and decreases steadily thereafter until telomerase activity is 
significantly decreased in irradiated cells at 120 and 240 hours post exposure (Figure 2.2 left 




significant elevation in telomerase activity in either the non-tumorigenic MCF-10a or the 
primary mammary epithelial AG11137 cell lines following IR exposure (Figure 2.2 middle and 
right panels).  A significant decrease in telomerase activity in AG11137 cells was observed at 48 
hours post exposure was observed, however, it is difficult to draw meaningful conclusions from 
this finding, as AG11137 cells are essentially telomerase negative to begin with.   
We conducted a similar study in hematopoietic cell lines following IR exposure and 
observed similar trends in cancer vs. non-cancer cell lines. Specifically, telomerase activity was 
significantly elevated in KG1a AML cells following exposures to both 1 and 4 Gy γ-rays, which 
persisted for up to 72 hours (Figure 2.3 left panel). A significant increase was detected in the 
non-tumor immortalized WTK1 cell line 24 hours post exposure to 4 Gy, which had disappeared 
by 48 hours post exposure and remained at background levels thereafter (Figure 2.3 middle 
panel). No significant changes in telomerase activity in the low passage normal LCL15044 cells 
were detected post exposure to either 1 or 4 Gy γ-rays (Figure 2.3 right panel).  
Our results suggest that elevation of telomerase activity following exposure to IR only 
occurs in cells possessing high levels of telomerase, like cancer cells, as the only cell lines to 
display a consistent increase telomerase activity were MCF-7 and KG1a. No significant 
elevation in telomerase activity was detected in the low telomerase positive MCF-10a cell line 
post exposure, nor in the normal AG11137 and LCL15044 cell lines. Thus, counter to our 
original hypothesis, telomerase is not significantly elevated post IR exposure in non-tumor cell 
lines, thus it is unlikely that telomerase is contributing to an extended replicative lifespan in these 
cells following exposure. To highlight this trend, Figure 2.4 illustrates a direct comparison of 
mammary epithelial cells (left panel) and hematopoietic cells (right panel), all relative to HeLa 




Telomerase Activity in Cell Lines Exposed to Low Dose Rate IR 
Epidemiological studies indicate that low dose rate exposures may be more carcinogenic 
than equivalent acute exposures (Gilbert, 2009). To determine whether telomerase activity is 
elevated in telomerase positive cell lines following chronic LDR exposures, we incubated the 
telomerase positive cell lines MCF-7, MCF-10a, KG1a, and WTK1 under LDR γ-ray exposures 
at dose rates of 4.9 or 3.12 cGy/hour for total accumulated doses of 1 and 4 Gy (Figure 2.5). 
Results suggest a dose rate dependent decrease in telomerase activity in all four cell lines 
examined that appears to be accentuated at cumulative doses of 1 Gy as opposed to 4 Gy. One 
possible explanation for this finding is that LDR exposure could be modifying the cell cycle 
distribution or potentially slowing overall cell growth enough to effect telomerase activity.  
 
Changes in hTERC and hTERT mRNA levels in mammary epithelial cells following Acute IR 
exposure 
To assess whether changes in telomerase activity were associated with changes in the 
expression of hTERT mRNA or hTERC RNA in MCF-7 and MCF-10a cells, and both of these 
genes are transcriptionally regulated, we utilized quantitative reverse transcriptase PCR (qRT-
PCR) to evaluate hTERT and hTERC levels post exposure to 10 Gy of γ-rays (Figure 2.6). 
Consistent with the observed elevation of telomerase activity in MCF-7 cells following IR 
exposure, both hTERT and hTERC levels were significantly elevated. hTERT levels, like 
telomerase activity, were significantly elevated at 24 hours post IR exposure and decreased 
thereafter, returning to background levels by 72 hour post IR. hTERC levels were significantly 
increased at 24 hours post IR exposure and increased from that point forward, remaining that 




telomerase activity observed post exposure observed in MCF-7 cells is associated with elevation 
in hTERT and hTERC RNA levels, but do not account for the significant decrease in telomerase 
activity detected at 120 hours post exposure. In contrast, MCF-10a cells experienced a 
significant decrease in hTERT and hTERC levels following exposure to 10 Gy γ-rays with the 
prior starting at 24 hours and the later beginning at 72 hours post exposure. While no overall 
decrease in telomerase activity associated with IR exposure was detected in MCF-10a cells, the 
lack of increased expression in these cells following IR exposure could explain why telomerase 
activity levels did not change. These findings are consistent with the idea that elevation of 
telomerase activity following IR exposure is a trait unique to cancer cells.  
 
Telomere Length Analysis of MCF-7 and MCF-10a Cells Exposed to Acute IR 
To assess whether changes in telomerase activity and hTERT or hTERC RNA levels led 
to an appreciable change in telomere length, we utilized interphase quantitative fluorescence in 
situ hybridization (Q-FISH) to assess changes in telomere length in MCF-7 and MCF-10a cells at 
120 hours post exposure to 10 Gy of γ-rays (Figure 2.7). Surprisingly, and despite an elevated 
telomerase activity in MCF-7 cells in the first several days post IR exposure, telomere length was 
reduced by ~20% at both the cell population level (Figure 2.7 top left panel) and the individual 
telomere level (Figure 2.7 lower left panel) relative to un-irradiated controls 5 days post IR 
exposure. A similar trend was observed in MCF-10a cells, with the only difference being that the 
observed decrease appeared to be greater at roughly 30% (Figure 2.7). The difference in the 
degree of telomere loss observed between MCF-7 and MCF-10a cells may be explained by the 





It has been demonstrated that cells with shorter telomeres tend to be more radiosensitive 
than cells with longer telomeres (Bailey & Cornforth, 2007; Genesca et al., 2006; Latre et al., 
2003; M'Kacher et al., 2007; K. K. Wong et al., 2000). However, this would suggest that cells 
containing shorter telomeres at the time of irradiation would be less likely to survive to 5 days, 
therefore truncating the histogram of individual telomere length on the left end (elimination of 
cells with short telomeres). This is not what we observed; rather it appears that all telomeres 
were shortened as a result of IR exposure shifting the normal distribution of individual telomere 
lengths to the left in both MCF-7 and MCF-10a cells (Figure 2.7 lower panel). These results 
suggest that an additional mechanism of telomere loss resulting from IR exposure is causing all 
telomeres to shorten disproportionately faster than un-irradiated cells, as opposed to selectively 
killing those cells with shorter telomeres at the time of irradiation.   
 
Discussion:  
Telomerase reactivation is a critical rate limiting step in the process of carcinogenesis and 
is required for cellular immortalization and tumor formation the vast majority of cancers (Shay & 
Wright, 2011). Consistent with previous reports, we found telomerase activity significantly 
increased in both MCF-7 mammary adenocarcinoma cells (Karimi-Busheri et al., 2010) and 
KG1a acute myeloid leukemia cells (Perez Mdel et al., 2002) for several days post-acute IR 
exposure. A possible explanation for this trend includes the idea that telomerase is playing a role 
in DNA repair (Bailey, 2008). However, Elkind et al previously demonstrated that most of the 
damage caused by low LET radiation is repaired within the first 2-12 hours following exposure 
(Elkind et al., 1965). Therefore, it is unlikely that telomerase is acting in a DNA repair capacity 




tumor repopulation by increasing the replicative potential of surviving clonogens. This concept is 
supported by a report by Padita et al that demonstrated telomerase activity was significantly 
elevated in relapsed, irradiated tumors in a mouse xenograft model (Pandita & Roti Roti, 2003; 
Sawant et al., 1999).  Pandita et al. speculated that telomerase activity may be used as a marker 
to predict the radio curability of solid tumors.     
We reasoned that telomerase activity may play a similar role in the process of 
carcinogenesis in normal, telomerase negative cells, and/or telomerase positive adult stem cells 
exposed to IR may utilize telomerase activity to increase their replicative lifespan and 
inadvertently propagate oncogenic mutations to their progeny, promoting tumor formation. 
However, our results tracking changes in telomerase activity in telomerase positive 
immortalized, non-tumorigenic mammary epithelial (MCF-10a) and lymphoblastoid (WTK1) 
cells yielded no significant increase in telomerase activity. Nor did we observe increases in 
telomerase activity in telomerase negative primary mammary epithelial cells (AG11137) or in 
telomerase positive low passage lymphoblastoid cells (LCL15044). One possible explanation for 
this finding could be activation of the G1/S phase checkpoint that several reports suggest acts in 
a negative feedback loop suppressing the transcription of the hTERT gene (Kanaya et al., 2000; 
Lai, Cunningham, Huynh, Andrews, & Tollefsbol, 2007; Xiang et al., 2002; Yang et al., 2007). 
Specifically, overexpression of p53 was shown to suppress telomerase activity in a variety of 
cancer cell lines due to increased levels of p21 protein (Xiang et al., 2002; Yang et al., 2007). 
Consistently, expression of hTERT in telomerase negative cell lines induced hyper 
phosphorylation of the retinoblastoma protein (Rb) promoting progression past the G1 
checkpoint into S-phase (Lai et al., 2007). Therefore, activation of the G1 checkpoint following 




activity in non-tumor cells, explaining the lack of an observed increase when regulation of these 
pathways is normal/functional. Conversely, in MCF-7 and KG1a cancer cells that lack a 
functional G1 checkpoint, regulation is lost and telomerase activity increases following IR. 
To further characterize the response of telomerase components hTERT and hTERC in 
MCF-7 and MCF-10a cells, we also examined changes in the levels of hTERT mRNA and 
hTERC in response to an acute 10 Gy exposure (Figure 2.6). Consistent with the increase in 
telomerase activity observed at 24 hours post exposure in MCF-7 cells, hTERT mRNA levels 
were significantly elevated starting at 24 hours post exposure and returned to background levels 
at 72 hours. hTERC RNA levels were also significantly elevated at 24 hours and steadily 
increased peaking at the 120 hour time point (latest time point examined). In contrast, both 
hTERT mRNA and hTERC were significantly decreased in MCF-10a cells following exposure, 
again highlighting that with regards to telomerase, the responses of tumor vs non-tumor is very 
different and is consistent with the checkpoint activation response described earlier.    
Epidemiologic studies have demonstrated that LDR exposure to IR is more carcinogenic 
than equivalent acute exposures (Gilbert, 2009). To our knowledge, we are the first group to 
examine the response of telomerase activity to LDR exposure. To determine whether LDR had a 
differential effect on telomerase activity compared to acute exposures, we incubated telomerase 
positive cells under standard conditions at dose rates of 4.9 and 3.12 cGy/hour for a time 
necessary to accumulate doses of 1 and 4 Gy. Surprisingly, LDR incubation appeared to have no 
significant effect on telomerase activity relative to un-irradiated controls in all of the cell lines 
examined (Figure 2.5). A statistically insignificant dose rate effect was observed as a dose rate of 
4.9 cGy/hour, which appeared to be more effective at reducing telomerase activity than 3.12 




 could be due to an increased cycling time resulting from LDR exposure effectively decreasing 
the need for cells to elongate telomeres and mitigate telomere loss because they are cycling more 
slowly.  
As the traditional role of telomerase is to elongate telomeres, a discussion of its effect on 
telomere length is crucial to any discussion of telomerase activity. Very little information exists 
on the effect of acute IR exposure on telomere length in dividing cells, however the work that 
has been done suggests simply that cells with shorter telomeres are more radiosensitive than cells 
with longer telomeres (Bailey & Cornforth, 2007; Genesca et al., 2006; Latre et al., 2003; K. K. 
Wong et al., 2000). To assess the effect of acute IR exposure, we examined telomere length in 
MCF-7 and MCF-10a cells at 120 hours post exposure to 10 Gy of γ-rays using interphase Q-
FISH (Figure 2.7).  
Counter to the expected findings, we observed a significant shortening of telomeres in 
both cell lines at the population level of approximately 20% in MCF-7, and a 30% decrease in 
MCF-10a. To further understand this change, we generated a histogram of the individual 
telomeres from the cells examined at the population level and superimposed the 0 and 10 Gy 
populations on top of each other. Rather than observing a selective elimination of specific 
telomeres, in both MCF-7 and MCF-10a cells, the length of all telomeres in the population were 
decreased effectively shifting the normal distribution of telomere lengths to the left (Figure 2.7 
lower panel).  This finding suggests an alternative mechanism that results in a general shortening 
of all telomeres, as opposed to a mechanism that selectively acts on shorter telomeres. 
Additionally, significant shortening of telomeres was observed in both tumor and non-tumor cell 




levels of telomerase both before and after exposure, whereas MCF-7 had elevated levels after 
exposure, which likely helped to mitigate telomere shortening to some extent.  
This finding also raises the issues of inducing genomic instability, one of Weinberg’s 
hallmarks of cancer (Hanahan & Weinberg, 2011). The significance of genomic instability and 
ties to cancer were first suggested by Nowell in 1976 and manifest in the form of random, 
ongoing mutation, gene amplification, and chromosomal changes (Nowell, 1976). Shortened 
telomeres have also been implicated as playing a role in promoting genomic instability as well as 
carcinogenesis (Kong, Lee, & Wang, 2013). The fact that IR shortens the entire population of 
telomeres implies that it will also induce instability; therefore surviving clonogens may have 
increased levels of instability leading to increased risk of tumor progression in non-cancer cells. 
Further, elevation in telomerase activity in cancer cells that appears to reduce overall telomere 
shortening may increase the survival of cancer cells, while also masking genomic instability and 
promoting metastasis or tumor recurrence following radiation therapy.  
Based on these findings, we conclude that the response of telomerase to IR exposure 
varies significantly between cancer and non-tumor cells. This is likely explained by the 
deregulation of telomerase that occurs during carcinogenesis and potentially results from the 
abrogation of functional cell cycle checkpoint machinery. LDR exposure also appears to 
effectively reduce telomerase activity indicating that dose rate is a critical factor to examine in 
future experiments. Furthermore, acute IR exposure causes telomere shortening in both normal 
and cancer cells, which appears to be mitigated by telomerase in cancer. This finding suggests 
that genomic instability can result from acute IR exposure generating critically short telomeres. 
Therefore the issue of telomeres and telomerase in the treatment and prevention of cancer is 




of telomerase. Future studies will seek to more clearly define this elaborate molecular interplay 




Figure 2.1: Telomerase activity relative to HeLa Cell Lysates in a panel of human cell lines. Left panel illustrates all cell lines 
examined and right panel demonstrates the same data, but with cell lines WTK1 and KG1a omitted to highlight differences in 
telomerase activity at low levels in normal and ALT cell lines. Based on these results, further analysis will consider cells with a 







Figure 2.2: Telomerase activity in mammary epithelial cells exposed to an acute dose of 10 Gy of γ-rays at various time points post 
exposure. Values are expressed as the percentage relative telomerase activity compared to an unirradiated control in MCF-7 
adenocarcinoma cells (left panel), MCF-10a non-tumor immortalized mammary epithelial cells (middle panel), and AG11137 primary 
mammary epithelial cells (right panel). Stars (*) represent data points which are significantly different from unirradiated controls as 












Figure 2.3: Telomerase activity in in hematopoietic cells exposed to an acute dose of 1 and 4 Gy  γ-rays at various time points post 
exposure. Values are expressed as the percentage relative telomerase activity compared to an unirradiated control in KG1a acute 
myeloid leukemia cells (left panel), WTK1 non-tumor immortalized lymphoblasts (middle panel), and LCL15044 primary 
immortalized low passage lymphoblast cells (right panel). Stars (*) represent data points which are significantly different from 





Figure 2.4: Telomerase activity in mammary epithelial cell lines exposed to acute doses of 10 Gy (left panel) and hematopoietic cell 
lines exposed to 1 or 4 Gy γ-rays (right panel). All data is scaled relative to unirradiated HeLa cell lysates (positive control) to provide 





Figure 2.5: Telomerase activity in telomerase positive cell lines exposed to cumulative doses of 1 or 4 Gy γ-rays at dose rates of 0, 
3.12, or 4.9 cGy/hr in MCF-7 (top left panel), MCF-10a (top right panel), KG1a (bottom left panel), and WTK1 (bottom right panel). 
Stars (*) represent data points which are significantly different from un-irradiated controls as determined by student’s t-test. Error bars 





Figure 2.6: Relative changes in hTERT (left panel) and hTERC (right panel) expression in MCF-10a (red bars) and MCF-7 (blue 
bars) in a five day timecourse a single acute exposure to 10 Gy of γ-rays at a dose rate of 2.5 Gy/min. Values represent expression 
changes relative to an un-irradiated control samples. Error bars represent standard deviation of the mean and stars (*) represent values 





Figure 2.7: Telomere length in MCF-7 and MCF-10a cells following 5 day incubation after a dose of 10 Gy γ-rays. Top left panel 
represents the average cell population telomere length in both un-irradiated controls and 10 Gy samples. Top right panel is a 
representative image of interphase nuclei hybridized with a Cy-3 telomere PNA probe utilized to generate telomere fluorescence 
intensities. Bottom panel is histograms displaying the length of individual telomeres in MCF-7 (bottom left) and MCF-10a (bottom 
right) cells following a 5 day incubation after 0 Gy (blue bars) or 10 Gy (red bars) exposures. Stars (*) represent values significantly 
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TELOMERASE REVERSE TRANSCRIPTASE ACTIVITY PROMOTES RADIATION 




 Cancer stem cells (CSCs) are a sub-population of highly clongoenic cells in human 
tumors that possess the embryonic stem cell (ES) like properties of self-renewal and the ability to 
differentiate along many lineages. CSCs are believed to be more radio resistant than their non-
stem cancer cell counter parts (NSCCs) and contribute to accelerated tumor repopulation 
following radiation therapy. Recent reports have shown that ionizing radiation (IR) exposure 
enriches putative CSCs in established human cancer cell lines. As telomerase plays a critical role 
in the maintenance of adult stem cells (ASCs), and we previously demonstrated that telomerase 
activity was elevated in human cancer cell lines following IR exposure, we reasoned that 
telomerase may promote radiation induced putative stem cell enrichment. In the studies 
presented here, we confirm previous reports of putative CSC enrichment in mammary carcinoma 
cells, and demonstrate CSC enrichment in non-cancer cell lines MCF-10a, WTK1, and 
LCL15044. Utilizing MST-312, a small molecule inhibitor of telomerase activity, we were also 
able to confirm that telomerase activity is critical for the enrichment of CSCs following IR 
exposure in telomerase positive breast cancer and non-cancer cell lines. Telomerase was not 
necessary for IR induced CSC enrichment in telomerase negative cancers. Taken together these 
findings imply that telomerase isn’t just for elongating telomeres anymore, and may play a more 
substantial role in carcinogenesis and tumor repopulation following radiation therapy than 






It has been previously demonstrated that almost all solid tumors and leukemias contain a 
subpopulation of primitive, highly clonogenic cells with self-renewing capability and the ability 
to differentiate along multiple lineages (Ailles & Weissman, 2007). When transplanted into 
immunodeficient mice, these cells were able to form tumors at much lower limiting dilutions 
than their more differentiated counterparts indicating a much higher invasive capacity (Bonfanti, 
Barrandon, & Cossu, 2012; Chen et al., 2013).  This sub population, regarded as cancer stem 
cells (CSCs), is thought be the driver of tumor progression, metastasis, tumor recurrence, and 
resistance to radiation and chemotherapy (K. Ogawa et al., 2013); thus, much effort has been 
allocated to understanding CSCs and identifying pathways that can be utilized to therapeutically 
target them.  
Ionizing radiation (IR) is commonly used to treat solid tumors due to its ability to 
selectively and effectively kill dividing cells (Hall, 2006). CSCs have long been regarded as 
more radio resistant than their more differentiated non-stem cancer cell (NSCC) counterparts. 
Proposed reasons for CSC increased radio resistance include: slower cycling times, enhanced 
DNA repair kinetics, elevated defenses against reactive oxygen species (ROS), and occupation of 
hypoxic tumor regions (K. Ogawa et al., 2013). Recently, experiments demonstrating the 
plasticity of cellular differentiation status with somatic cell nuclear transfer (SCNT) (Tachibana 
et al., 2013) and transcription factor mediated nuclear reprogramming (Takahashi et al., 2007; 
Zaehres & Scholer, 2007) indicate an ability to interconvert between cellular niches, specifically 
CSCs and NSCCs. Because of this, it can be inferred that CSC radio resistance is a transient 
cellular property governed by reprogramming factors and differentiation status rather than 




It has been demonstrated that therapeutically relevant doses of IR induce the enrichment 
of CSCs in established human tumor cell lines including mammary carcinoma (Phillips et al., 
2006), colorectal cancer (Cui et al., 2011),  and lung cancer (O'Flaherty et al., 2012). It was 
originally believed that such stem cell enrichment was the result of selection of the radio 
resistant CSC population surviving and dividing to repopulate the tumor. However, it has 
recently been shown by Lagadeck et. al. that IR can induce reprogramming (inter-conversion) of 
NSCCs into CSCs in mammary carcinoma cell lines (Lagadec et al., 2012). Furthermore, Hei et 
al. demonstrated that reprogramming occurs at background levels to maintain an equilibrium 
percentage of CSC’s and that IR accelerated the inter-conversion kinetics (Yang et al., 2012).  
Thus, both selection of radio resistant CSCs and reprogramming of NSCCs into CSCs are likely 
contributing to stem cell enrichment post IR exposure. Importantly, CSC enrichment has been 
linked to accelerated tumor repopulation following radiation therapy (K. Ogawa et al., 2013; 
Trott, 1994). Gaining a deeper understanding of the molecular mechanisms involved in CSC 
enrichment following IR could therefore provide novel therapeutic targets with the potential to 
improve the efficacy of radiation therapy. 
Telomerase activity is required for maintaining telomere length and prolonging cellular 
lifespan in embryonic stem (ES) and adult stem cell (ASC) populations, and is also high in 
NSCCs (Shay & Wright, 2011). Interestingly, cancer cell lines that have been enriched for CSC 
populations by way of addition of defined growth factors (sphere forming assay) have been 
shown to have higher telomerase activity than cultures with much lower percentages of CSCs 
(Karimi-Busheri et al., 2010). This has led us to hypothesize that previously reported elevations 
in telomerase activity following acute IR exposure in cancer cell lines may be the result of CSC 



















) following IR exposure. Further, 
we employed a small molecule inhibitor of telomerase activity to evaluate a potential role for 
telomerase in radiation induced stem cell enrichment.  
Results suggest that radiation induced stem cell enrichment is a general phenomenon 
applying to mammary epithelial, hematopoietic, and osteosarcoma cell lines. Additionally, and to 




 CSC cell enrichment in the 
non-tumorigenic MCF-10a cell line, cells that upon reprogramming have been shown to lead to 
tumor formation and metastasis when injected into immunodeficient mice. Furthermore, 
elevation of telomerase activity appears to precede cancer stem cell enrichment in MCF-7 
adenocarcinoma cells. It was inversely associated with stem cell populations in KG1a acute 
myeloid leukemia (AML) cells. Enrichment occurred in non-tumorigenic cell lines (MCF-10a, 
LCL15044, and WTK1) despite no significant changes in telomerase activity with IR, as well as 
in osteosarcoma cell lines U20S and SAOS2 which maintain telomeres using the telomerase 
independent alternative lengthening of telomeres (ALT) pathway.  Additionally, small molecule 
inhibition of telomerase activity blocked radiation induced stem cell enrichment in both MCF-7 
and MCF-10a cells despite the later having no detectable increases in telomerase activity 
associated with IR exposure. Additionally, small molecule inhibition of Tankyrase 1 (TNKS1) 
and DNA dependent protein kinase catalytic subunit (DNA-PKcs), important players in 
regulation of telomere structure and function, had no discernable effect on stem cell enrichment 
following IR.  
We found that elevated telomerase activity post IR exposure temporally preceded CSC 




small molecule inhibition of telomerase activity demonstrated that it is necessary for radiation 
induced stem cell enrichment following IR exposure in telomerase positive backgrounds. Thus, 
our results support telomerase inhibition as a potentially effective strategy to prevent 
radiotherapy induced CSC enrichment and reduce tumor recurrence. 
  




The human mammary epithelial non-tumorigenic cell line MCF-10a was purchased from 
ATCC and was cultured as described previously (Le et al., 2013) in 1:1 Dulbecco’s Modified 
Essential Medium (D-MEM)/Ham’s F12 growth medium (Hyclone) supplemented with 5% fetal 
bovine serum (FBS), 10 µg/mL insulin (Sigma), 20 ng/mL epidermal growth factor (EGF; 
Sigma), 0.5 µg/mL hydrocortisone (Sigma), 0.1 µg/mL cholera toxin (Sigma), and 1% glutamax 
(Life Technologies). The human mammary carcinoma cell line MCF-7 (kind gift from L. Chubb, 
CSU Animal Cancer Center) was grown in D-MEM supplemented with 10% FBS and 1% 
glutamax. The primary mammary epithelial cell line AG11137 (Coriell) was grown in MCDB 
170 complete growth medium (US biological) supplemented with 5 µg/mL insulin, 10 ng/mL 
EGF, 0.5 µg/mL hydrocortisone, 56 µg/mL bovine pituitary extract (Life Technologies), and 1% 
glutamax. A human primary immortalized, low passage lymphoblast cell line (LCL15044 kind 
gift from A. Sigurdsson, National Institute of Health) was grown in RPMI medium supplemented 
with 15% FBS and 1% glutamax. The WTK1 immortalized lymphoblast cell line (kind gift from 
H. Liber, Colorado State University) was grown in RPMI medium supplemented with 10% fetal 
horse serum and 1% glutamax. Human acute myeloid leukemia cells KG1a (Kind gift from 




and 1% Glutamax. The human osteosarcoma ALT cell lines U2OS and SAOS2 (kind gift from 
D. Gustafson Colorado State University Animal Cancer Center) were grown in McCoy’s 5A 
growth medium (Life Technologies) supplemented with 10% FBS and 1% glutamax. All cells 
were grown at in a humidified incubator at 37
O
C in 5% CO2 and passaged 1-2 times per week. 
Cells were grown at 37
o




Cells were exposed to various, acute doses of 
137
Cs γ-rays in a Mark I irradiator (J.L. 
Shepherd) located at Colorado State University. Cells were exposed at a dose rate of 2.5 Gy/min 
with rotation.  
 
Clonogenic Cell Survival 
 
Cells were seeded at ~50% density in T-25 culture flasks 48 hrs prior to irradiation. 
Following irradiation at doses of 0, 1, 2, 4, 8, and 10 Gy of γ-rays, cells were trypsinized, 
resuspended at low density, and plated to allow for 30-50 colonies in 30 mm cell culture dishes 
(TPP Cell Culture). Cells were grown for ~10 population doublings (10-14 days), fixed using 
100% ethanol, and stained using 5% crystal violet (Sigma). Colonies were scored based on the 









 surface markers (Phillips et al., 2006; Sheridan et al., 2006; Sun et al., 2012). 















(L. Yu et al., 
2013). All analyses were performed on a CyAn ADP Analyzer with 9-color capability (Beckman 
Coulter CY20130) located at the Colorado State University Veterinary Teaching Hospital.  
 
Staining for cancer stem cell markers  
 
Monolayers MCF-7 and MCF-10a mammary epithelial cells were trypsinized and stained 
for CD44 and CD24 expression as described previously (Lagadec et al., 2012; Lagadec et al., 
2010; Sheridan et al., 2006). Briefly, ~300,000 cells were dissociated from cell culture surface 
using 0.25% Trypsin-EDTA, pelleted, washed, and resuspended in 30 uL of Flow Cytometry 
wash buffer (1X PBS, 1% FBS, and 1% Penicillin/Streptomyocin). 6 µL of direct FITC 
conjugated mouse monoclonal anti-human CD44 antibody (BD Pharmingen #555478) and 6 µL 
of direct PE conjugated mouse monoclonal anti-human CD24 antibody (BD Pharmingen 
#555428). Cells were then incubated for 30-60 min in the dark at 4
O
C. Following incubation 
cells were pelleted and resuspended in 500 µl of cold 1X PBS and kept on ice until analysis. 
Analysis gates were established using cells from unstained controls and anti-mouse Ig,κ antibody 
capture beads (BD Pharmingen #552843). For lymphoblastoid suspension cultures, cells were 
stained as above with 6 µL of direct PE conjugated mouse monoclonal anti-human CD34 
antibody (BD Pharmingen #555822) and 6 µL of direct FITC conjugated mouse monoclonal 
anti-human CD38 antibody (BD Pharmingen #560982). Assessment of CSCs in Osteosarcoma 
cell lines was done as described above using anti-human CD44 antibody and anti-human 








Quantitative Real Time PCR Based Telomere Repeat Amplification Protocol (TRAP) 
 
Telomerase activity was detected via the telomere repeat amplification protocol (TRAP) 
assay originally described by Herbert (Herbert et al., 2006) et al and adapted for real time PCR 
by Hou et al (Hou et al., 2001). Briefly, whole cell lysates were prepared from cultured cell 
pellets, lysed in cold MPER mammalian protein extraction buffer (Thermo Fischer) containing a 
protease inhibitor cocktail (Roche) and RNasin ribonuclease inhibitor (Promega) at a ratio of 100 
µl of buffer per 1,000,000 cells. Lysates were cleared by centrifugation at 14,000 RPM for 10 
minutes at 4
o
C, aloiquotted, and stored at -80
o
C. Protein concentration was determined using the 
Bradford Assay (Biorad).   
The SYBR green master mix (Promega) included all necessary components to complete 
the RTQ-PCR reaction. Each well contained between 0.1 and 0.25µg of protein lysate, 50% 
volume of SYBR green master mix, 0.2µg T4 gene32 protein (New England Biolabs, Ipswitch, 
MA), 0.1µg of each primer TS (5’-AATCCGTCGAGCAGAGTT- 3’) and ACX (5’-
GCGCGG(CTTACC)3CTAACC-3’) (Integrated DNA Technologies) and RNase/DNase free 
water to achieve a final well volume of 25ul. The PCR and detection were performed on a CFX 
96 (Biorad). In addition to the treatment samples, a series of controls were also included on each 
plate: (1) no template control with TS primer only, (2) no template control with ACX primer 
only, (3) no template control with TS and ACX primers (used in normalization of samples), (4) 
heat inactivated control with template (protein lysate) and TS and ACX primers, (5) HeLa cell 
lysate with TS and ACX primers (a positive control with robust telomerase activity).  
The RTQ-PCR program includes the following steps: Step 1- 1cycle 25℃ 20 min (telomerase 
elongates the TS primer by adding TTAGGG repeat sequences); Step 2- 1cycle 95℃ 3 min (heat 




30 sec and 72℃ for 1min 30 sec (PCR amplification allows for detection by real time 
instrument); Step 4- 80 cycles 0.10 sec per cycle (melt curve to  ensures no primer dimer 
formation). Each sample is run in triplicate on a 96 well plate format allowing for an average Ct 
to be obtained per sample. Utilizing the average Ct value, the relative percent telomerase activity 
in each sample is calculated using the Delta Delta Ct method (2
-ΔΔCT
) (Livak & Schmittgen, 
2001). Briefly, to calculate the percent relative activity for each sample first normalize the 
average sample Ct to the no template control with TS and ACX primers. This is referred to as the 
delta Ct value. The delta Ct value of each sample is subtracted from the delta Ct value of a 
chosen comparative sample, in this case a normal feline mucous membrane cell lysate, yielding a 
delta delta Ct value (∆∆Ct). Using the 2
-ΔΔCT
, a relative value is generated for each sample 
comparison and when multiplied by 100 is the relative percent of telomerase activity (RTA) of 
the sample compared to the normal feline mucous membrane. The RTA can be compared 
between samples assayed across different plates. Results from two runs were averaged. 
 
Small Molecule Inhibiton 
Inhibition of telomerase activity was accomplished through the use of MST-312 (Sigma) 
also known as telomerase inhibitor IX (Seimiya et al., 2002). Inhibition of tankyrase 1 (TNKS1) 
was accomplished through the use of inhibitors XAV-939 (ToCris) and IWR-1 (Sigma) (Bao et 
al., 2012; Narwal, Venkannagari, & Lehtio, 2012). Nu7026 (Sigma) was used to inhibit DNA-
PKcs kinase activity (Le et al., 2013). Briefly, all inhibitors were solubilized at concentrations 
recommended by the manufacturer in sterile DMSO, aloiquotted, and stored at -20
O
C for no 
more than 1 month prior to use. MST-312 was added to cultures 6 hours prior to experimentation 




Thiazolyl Blue Tetrazolium Bromide (MTT) Assay  
 
Potential cytotoxic effects of the telomerase inhibitor MST-312 were determined through 
the use of the MTT assay as described previously (Bes et al., 2004). Briefly 2000 cells per well 
of a 96-well plate were seeded 24 hours prior to addition of inhibitor. Media was removed from 
wells and fresh media containing varying concentrations of MST-312 or an equivalent DMSO 
control were added to all wells. Cells were incubated in the presence of inhibitor for 48 and 72 
hours. At the time of analysis, media was once again removed from wells, and cells were 
resuspended in fresh media containing 0.5 mg/ml MTT reagent and incubated at 37
O
C for 3.5 
hours. Following incubation, media was removed and 150 µl of MTT solvent (4mM HCl, 0.1% 
NP-40, all in isopropanol) was added to each well and set to agitate on a shaker at room 
temperature for 15 min. After agitation, plates were read on a Modulus Microplate reader 
(Turner Biosystems) at 600 nm absorbance.  
 
Statistical Analyses 
 Statistical differences were detected using a Student’s t-test against relevant controls. 




Ionizing Radiation Induced Breast Cancer Stem Cell Enrichment 
 
Breast cancer cell populations grown on low adherence plates containing selective media 
form structures known as mammospheres (Joseph et al., 2010; Karimi-Busheri et al., 2010; Xie 




 breast CSCs and have been 




2006) supporting breast CSCs having higher telomerase activity than NSCCs. Further, ionizing 
radiation has been shown to enrich CSC population in monolayer cultures of established cancer 
cell lines for breast (Al-Hajj et al., 2003), lung (O'Flaherty et al., 2012), colon (Yang et al., 
2012), and glioblastoma (Hale, Sinyuk, Rich, & Lathia, 2013). Such findings led us to originally 
hypothesize that the elevated telomerase activity following exposure to acute doses of ionizing 
radiation, might result from CSC enrichment following IR exposure.  
Consistent with previous reports, breast cancer stem cells were enriched in MCF-7 cell 
populations at 5 days post exposure (Figure 3.1). Unexpectedly, we also observed a significant 
increase in CSCs in MCF-10a cells at 5 days post IR exposure. To our knowledge, we are the 
first to report this finding and it suggests that IR induced CSC enrichment may play a role in the 
transformation of non-tumor tissues. In earlier studies, we demonstrated that telomerase activity 
was significantly elevated within MCF-7 cells in the first 48 hours post IR exposure, and that by 
120 hrs, telomerase activity had dropped below levels observed in un-irradiated cells. Therefore, 
at least in MCF-7 cells, stem cell enrichment (occurring at 120 hours post IR exposure) does not 
seem to temporally correlate with changes in telomerase activity. Furthermore, CSC enrichment 
was also observed in MCF-10a cells, which did not exhibit a significant change in telomerase 
activity following IR exposure. Thus, it appears as though our original hypothesis was incorrect, 
in that fluctuations in telomerase activity post IR (occurs 24-48 hr) do not appear to be 
temporally associated with enrichment of breast cancer stem cell populations (occurring at 120 
hr).  
To further characterize breast cancer stem cell enrichment in MCF-10a cells, we tracked 
stem cell enrichment relative to un-irradiated controls for 10 days post exposure to 10 Gy of γ-




steadily declined thereafter, returning to background levels 168 hr after exposure. We also 
examined potential dose dependence of CSC enrichment in MCF-10a cells, as a threshold dose 
had been previously demonstrated in breast cancer cell lines (Lagadec et al., 2010). Stem cell 
enrichment did not occur at doses of 5 Gy and below, but a dose response was detected at 10 and 
20 Gy (Figure 3.3 bottom panel). Therefore, a threshold dose necessary to trigger CSC 
enrichment is between 5 and 10 Gy (γ-rays) and beyond that threshold,  increased dose appears 
to enrich CSC populations in a dose dependent manner.      
 
Potential Role of IR Induced CSC Enrichment in Tumor Repopulation Following Radiation 
Therapy  
 
It has been suggested that CSCs play a crucial role in the accelerated repopulation of 
tumors following radiation therapy (Trott, 1994). Originally, it was believed that populations of 
radio-resistant CSCs existing in a tumor were better to able to survive radiation therapy, and 
once mobilized through accelerated asymmetric cell division repopulated the NSCCs and the 
bulk tumor (Butof et al., 2013; K. Ogawa et al., 2013). However, recent experimental evidence 
suggesting plasticity of the stem cell niche, including successful nuclear reprogramming 
(Takahashi et al., 2007), somatic cell nuclear transfer (Tachibana et al., 2013) of human cells, 
and more recently radiation induced reprogramming of NSCC into CSCs (Lagadec et al., 2012; 
Yang et al., 2012), have raised a critical question: is cancer stem cell enrichment following 
radiation therapy a result of selecting for existing CSCs or a result of the NSCCs being converted 
into CSCs?    
Experimentally this is a very difficult question to answer, however we examined growth 
kinetics of both MCF-7 and MCF-10a cells following exposure to 10 Gy of γ-rays to tease out an 




surviving radiation at an acute dose of 10 Gy (Figure 3.2 top panel). In the case of both the 
MCF-7 and MCF-10a cells, survival was below 1% suggesting that 10 Gy reproductively killed 
most of the cells in the culture. However, despite few surviving cells, the cell populations 
continued to divide for at least 5 days, although at a much slower rate in both cases (Figure 3.2 
middle panel). From this, it could be assumed that surviving cells (presumably the existing 
CSCs) are repopulating the tumor in a process akin to selection. However, cell cycle analysis 
using propidium iodide (PI) staining and flow cytometry in MCF-10a cells, revealed very few 
cycling cells at later time points, suggesting CSC enrichment is resulting from inter-conversion 
or reprogramming rather than selection (Figure 3.2 bottom panel). Further experimentation is 
necessary to understand this complex relationship, however contrasting results suggest that both 
selection and reprogramming play a role in IR induced stem cell enrichment.   
    
IR Induced CSC Enrichment in Hematopoietic Cell Lines 
 
To determine if IR induced stem cell enrichment was a phenomenon unique to solid 
tumor cell lines, we tracked the proportion of CD34
+ 
cells in immortalized primary (LCL15044) 
and p53 mutated (WTK1) lymphoblastoid cell lines. CD34 is a classical marker of primitive 
hematopoietic stem cells and is commonly associated with CSCs in leukemia and lymphoma cell 
lines  and exists at low levels in differentiated lymphocytes (Bonnet & Dick, 1997; Calloni, 
Cordero, Henriques, & Bonatto, 2013). We exposed suspension lymphoblast cultures to acute 
doses of 1 or 4 Gy γ-rays and tracked CD34
+
 cell populations for up to 120 hours post IR 
exposure (Figure 3.4). Both the WTK1 and LCL15044 cell lines displayed a dose and time 
dependent increase in the percentage of CD34
+
 cells (Figure 3.4 top and middle panels). This 




IR induced enrichment of more primitive cell populations in non-cancer cell lines; a finding with 
important implications for carcinogenesis and in particular secondary cancers following radiation 
therapy.  




 CSC population in KG1a acute 
myeloid leukemia (AML) cells following acute exposures to 1 and 4 Gy up to 72 hours post IR 
(Figure 3.4 bottom panel). Interestingly, CSC percentages in this cell line were decreased in a 
dose dependent manner. This was the only observed exception to IR induced stem cell 
enrichment observed in all other cell lines. One possible explanation is that KG1a is therapy 
induced leukemia, and therefore may respond very differently to IR (Mrozek, Tanner, Heinonen, 
& Bloomfield, 2003). Additionally, as KG1a has a relatively high background population of 
CSCs, it is possible that the CSC population is more heterogeneous in its radiation sensitivity. 
Taken together with the studies conducted using breast cancer stem cell markers, we can 
conclude that changes in telomerase activity do not correspond with increases in CSC 
populations.  
 
Telomerase Reverse Transcriptase Activity in IR Induced CSC Enrichment 
 
As significant elevation of telomerase activity preceded enrichment of CSC populations 
in irradiated MCF-7 cultures, we hypothesized that telomerase activity is necessary for 
enrichment to occur following IR. To test this hypothesis we utilized the small molecule 
inhibitor MST-312, which non-covalently binds to the reverse transcriptase domain of the 
telomerase catalytic subunit effectively blocking its activity (Seimiya et al., 2002). MST-312 
effectively reduced telomerase activity as verified by TRAP assay at 1 µM doses in MCF-10a 




Cytotoxicity of MST-312 was determined via MTT assay. It was determined that future 
experiments would be conducted with both 1 and 3 µM doses in MCF-7 cells, and at a 1 µM 
dose in MCF-10a cells to avoid complications from cytotoxicity (Figure 3.5 middle panel). 
Essentially doses of MST-312 were chosen that gave minimal cytotoxicity while still achieving a 
reasonable level of telomerase inhibition. MST-312 was added to cultures 6 hours prior to 
irradiation to allow for binding and inhibition to occur. Cultures were then irradiated with 10 Gy 




 breast CSC 
populations (Figure 3.5 bottom panel). Doses of MST-312 (1 µM) effectively blocked radiation 
induced CSC enrichment in MCF-10a and MCF-7 (3 µM) cells. This is consistent with the much 
higher background levels of telomerase activity in MCF-7 cells as compared to MCF-10a. MST-
312 did not appear to effect background levels of CSCs in either cell line examined. These 
findings suggest that telomerase activity is necessary for CSC enrichment following IR.        
To further evaluate the role of telomerase in IR induced stem cell enrichment, we 




) putative CSC enrichment in the U2OS and 
SAOS2 osteosarcoma cell lines which maintain their telomere length via the ALT pathway (L. 
Yu et al., 2013). To our surprise, both osteosarcoma cell lines displayed a significant increase in 
CSC percentages at 5 days post exposure to 15 Gy (Figure 3.6 top panel). A dose of 15 Gy was 
chosen in this case, as previous reports suggested that osteosarcoma cells are more radio-resistant 
than carcinomas. These findings suggest that more than telomerase is at play in this finding and 
other pathways may be acting in accordance or substituting for the lack of telomerase activity in 
ALT cell lines. Thus, despite the fact that telomerase inhibition prevented IR induced CSC 
enrichment in telomerase positive cancers, it does not appear to be required for that same 




Inhibition of Telomerase, Not Other Telomere Related Pathways Prevents IR Induced Stem Cell 
Enrichment           
 
To determine if blocking telomerase activity prevented IR induced stem cell enrichment 
through direct loss of telomerase activity or general effects on telomere structure, we repeated 
previous experiments using inhibitors known to affect telomere structure. TNKS1 is a poly ADP-
ribose polymerase which post-translationally modifies proteins (PARsylation) by adding chains 
of NAD
+
 groups that affect binding properties (S. M. Huang et al., 2009; Smith et al., 1998). 
TNKS1 PARsylates the telomere repeat binding factor 1 (TRF1), leading to TRF1 dissociation 
from the telomere chromatin structure and facilitating access by telomerase (Hsiao & Smith, 
2008). Loss of TNKS1 leads to telomere shortening and instability (Smith & de Lange, 2000). 
DNA-PKcs kinase activity is also critical for appropriate telomere end capping function, as its 
loss results in telomere telomere end fusions and telomere-double strand break fusions (Bailey, 
Brenneman, et al., 2004; Fabre et al., 2011).  
We utilized small molecule inhibitors directed against TNKS1 (XAV-939 and IWR-1) 
and DNA-PKcs (Nu7026) to induce telomere dysfunction in MCF-10a cells. Cells were treated 





 stem cell populations 5 days post IR (Figure 3.7).  None of these 
reagents were effective at blocking radiation induced CSC enrichment. Interestingly, XAV-939 
and IWR-1 treatment appeared to significantly elevate background levels of CSCs in the cell 
population, while treatment with Nu7026 significantly decreased background levels. These 






Cancer stem cells are thought to drive carcinogenesis and underlie solid tumor recurrence 
following treatment (Butof et al., 2013). This concept has promoted a great deal of research to 
better understand and target existing CSCs in order to improve clinical outcomes (Chen et al., 
2013). Foremost among such examples would be the successful conversion of non-stem human 
cells into pluripotent stem cells through the processes of transcription factor mediated nuclear 
reprogramming or somatic cell nuclear transfer. These studies highlighted cellular plasticity and 
fluidity of the stem cell niche in both cancer and normal tissues, and supported the potential to 
contribute to carcinogenesis and tumor repopulation following radio therapy. 
Here, we sought to establish a causative link between telomerase, the reverse 
transcriptase critical in maintaining the human ASC niche, and cellular plasticity-specifically the 





cells that have been identified as putative breast CSCs in human tumors, and exhibit the ability to 
self-renew and differentiate along multiple lineages (Al-Hajj et al., 2003; Fillmore & 
Kuperwasser, 2008). It has been shown that a population of breast CSCs exists in established 
cultured tumor cell lines (Fillmore & Kuperwasser, 2008; Ponti et al., 2005), and further that 
exposure to IR significantly enriched this population (Lagadec et al., 2012; Lagadec et al., 2010; 










 cells require much lower limiting dilution to form tumors in mice (Ponti 
et al., 2005), and exposure to IR enriches this population, it is highly likely that clongoenic 








 cells in 




 cells had 
previously been documented in this cell line, however it was uncertain whether these breast 
CSCs possessed the same properties as CSCs from metastatic tumor cultures (Sheridan et al., 
2006). MCF-10a cells have been reprogrammed to pluripotency through the introduction of 





(Nishi et al., 2014). Reprogrammed MCF-10a cells were able to form tumors in nude mice, 
whereas their more differentiated/non-reprogrammed counterparts were not, indicating that this 
reprogrammed population did indeed exhibit properties of CSCs. These results have important 
implications for carcinogenesis, because IR exposure appears to be enriching MCF-10a cells for 
a population with tumor promoting properties. Further, characterization of MCF-10a stem cell 




 cells at 120 hours post IR 
exposure that appeared to have dose dependence above a threshold around 10 Gy.   
The lymphoblastoid cell lines WTK1 and LCL15044 also displayed a significant increase 
in cells expressing the hematopoietic stem cell (HSC) marker CD34 following IR exposure 
(Figure 3.4). CD34 is a cell surface glycoprotein believed to mediate the attachment of HSCs to 
the bone marrow extracellular matrix (Simmons, Satterthwaite, Tenen, & Seed, 1992) that is 
used as a marker for CSCs in various types of leukemia (Calloni et al., 2013). Radiation doses of 
both 1 and 4 Gy induced stem cell enrichment evidenced by the increased percentage of cells 
expressing CD34. This finding suggests that radiation induced stem cell enrichment is not 
restricted to cells of epithelial origin, but that it also presents a carcinogenic risk to other cell 
types, as it occurs in hematopoietic cells. The only exception to stem cell enrichment following 








population of leukemic CSCs (Hoang, Zepeda-Moreno, & 
Ho, 2012). Following exposures to both 1 and 4 Gy, KG1a cells displayed a significant decrease 




CSCs indicating that radiation selectively eliminated the CSC 
population.  
It has long been assumed that enrichment of CSCs following radiation therapy in human 
tumors and established cancer cell lines resulted from the more radio resistant CSCs surviving to 
repopulate the tumor following injury (K. Ogawa et al., 2013). However, it was recently 
demonstrated that sorted populations of near-pure breast NSCCs exposed to therapeutically 
relevant doses of IR were reprogrammed into a more stem like state (Lagadec et al., 2012; Yang 
et al., 2012). This important observation that IR triggers the inter conversion of NSCCs into 
CSCs, suggests IR-induced CSC enrichment results from more than simply selecting for existing 
radiation resistant stem cells, and further that the radio-resistant properties CSC exhibit may be a 
transient cellular property rather than specific cell state. Indeed, when pure populations of sorted 
breast and colon NSCCs and CSCs were maintained in long term culture, both eventually 
returned to the background percentages of CSCs identified in unsorted culture (Gupta et al., 
2011). Return to this background equilibrium state was accelerated in both directions through 
exposure to IR, suggesting the activation of pathways that maintain a sort of kinetic homeostasis 
(Yang et al., 2012). Thus, to effectively eliminate CSCs over the course of radiation therapy, not 
only must existing CSC populations be targeted, but the inter conversion of NSCC into CSC 
must also be blocked to most effectively prevent IR induced stem cell enrichment and 
accelerated tumor repopulation. 
Our previous findings (Chapter 2) demonstrated that telomerase activity was elevated in 









(Karimi-Busheri et al., 2010), we originally hypothesized that telomerase activity was elevated 
due to enrichment of CSC populations. However, in the case of MCF-7 cells, telomerase activity 
was elevated from 24 to 48 hours, whereas CSC enrichment did not occur until 120 hours post 
exposure. KG1a cells, which had significantly elevated levels of telomerase activity post IR, 
displayed decreased levels of CSCs at the same time. Furthermore, the non-cancer cells MCF-
10a, WTK1, and LCL15044 had significantly elevated levels of CSC markers in cells exposed to 
IR, despite a lack of change in telomerase activity. Therefore, CSC enrichment is not associated 
with increased telomerase activity.  
Recent reports linking telomerase to pathways that promote “stemness” including Wnt/β-
catenin and NF-κB signaling, and recent reports of hTERT transfection in ALT cells inducing 
stem cell enrichment (L. Yu et al., 2013) caused us to rethink our hypothesis (Choi et al., 2008; 
Hoffmeyer et al., 2012; Low & Tergaonkar, 2013; Stower, 2012). Because telomerase activity 
was elevated prior to the enrichment of breast CSCs, perhaps it was acting to promote 
“stemness” upstream of CSC enrichment. To test this hypothesis we treated MCF-7 and MCF-
10a cells with the telomerase inhibitor MST-312 6 hours prior to irradiation. MST-312 is a small 
molecule inhibitor of telomerase activity that, blocks its reverse transcriptase activity by non-
covalently binding to the elongation cleft of hTERT (Seimiya et al., 2002). Telomerase inhibition 
effectively blocked CSC enrichment resulting from IR, but did not appear to effect background 
levels of CSC populations in MCF-7 cells. Interestingly, telomerase inhibition had the same 
effect in MCF-10a cells despite a lack of telomerase activity increase following IR exposure. 
Thus, while changes in telomerase activity following IR exposure does not  temporally associate 




results suggest that telomerase inhibition can block stem cell enrichment regardless of whether it 
occurs via selection of surviving CSCs or through reprogramming.  
Since telomerase activity was necessary for IR induced CSC enrichment in mammary 
epithelial cells, we next asked whether CSCs in osteosarcoma cell lines that maintain telomere 
length through the telomerase independent, ALT pathway were able to be enriched following IR 




 CSCs were recently described in osteosarcoma cells 
(L. Yu et al., 2013). Following exposure of the osteosarcoma cell lines U20S and SAOS2 to an 




 cells in the population 5 days post IR 
exposure was determined. Interestingly, these cell lines were also enriched for CSCs despite the 
lack of telomerase activity. Therefore, while telomerase activity may be required for the efficient 
CSC enrichment in telomerase positive breast cancer cell lines, it is not required for CSC 
enrichment in telomerase negative, ALT cancer cell lines.  
This finding led us to ponder whether the absence of breast CSC enrichedment following 
IR exposure upon telomerase inhibition was due to lack of telomerase activity or a disruption of 
telomere structure. Telomerase positive cell lines display accelerated telomere shortening and 
instability under telomerase inhibition (Bechter, Zou, Walker, Wright, & Shay, 2004). By this 
reasoning, if enrichment was blocked due to telomere dysfunction rather than lack of telomerase 
activity in telomerase positive cancer, inhibiting telomerase activity would not induce telomere 
dysfunction in ALT. To test this hypothesis, we induced telomere dysfunction utilizing small 
molecule inhibitors directed against TNKS1 and DNA-PKcs, proteins which are important for 
appropriate telomere maintenance, but not directly related to telomerase. TNKS1 is a PARP that 
covalently modifies TRF1, a component of shelterin which directly binds telomere double 




telomere shortening independent of telomerase activity (Smith & de Lange, 2000). DNA-PKcs is 
a protein required for classical DNA double strand break repair via non-homologous end joining 
(NHEJ) that is also necessary for the appropriate capping function of telomeres (Bailey, 
Brenneman, et al., 2004). Loss of DNA-PKcs kinase activity leads to telomere-telomere fusions 
and other markers of telomere instability (Bailey & Goodwin, 2004). Neither inhibition of 
TNKS1 nor DNA-PKcs prevented IR induced CSC enrichment in MCF-10a cells, supporting the 
need for telomerase in IR induced enrichment. Interestingly, while TNKS1 inhibition was unable 
to prevent IR induced CSC enrichment, it significantly elevated background levels of CSCs in 
MCF-10a cells without irradiation. It is possible that the connection between TNKS1 and TRF1 
explains this finding, as TRF1 was recently demonstrated to be necessary for maintenance of the 
adult stem cell niche (Schneider et al., 2013), however further experimentation must be 
conducted to establish such a link. Further experimentation is necessary to determine what cells 
are actively dividing and potentially contributing to IR induced stem cell enrichment. Agent 
based mathematical modeling as well as future experimentation assessing the fraction of S-
phase, apoptotic, and senescent cells will help to determine if IR induced putative stem cell 
enrichment is a result of the mobilization of existing, and inherently radio-resistant stem cell 
populations, or resulting from reprogramming. 
Throughout the course of this study we have demonstrated IR induced CSC enrichment 
in various cancer and normal cell lines. These findings highlight a potential opportunity to 
enhance clinical radiation therapy through the targeting of processes that influence CSC 
enrichment, thereby slowing or preventing accelerated tumor repopulation. Furthermore, the 
demonstration of IR induced enrichment of CSC populations in non-tumor cell lines suggests 




radiation therapy. We have identified telomerase inhibition as an effective candidate in 
accomplishing such goals. Future studies will seek to more clearly define the role of telomeres 
and telomerase in IR induced CSC enrichment, as well as identify other pathways that may be 









 breast cancer stem cells in MCF-7 and MCF-10a 
cell lines 5 days post exposure to an acute dose of 10 Gy of γ-rays. Top panel illustrates 
representative scatter plots generated using flow Cytometry and bottom panel illustrates the 




cancer stem cells. Error bars 
represent the standard deviation of the mean and stars (*) represent values which are 






Figure 3.2:  Cell growth dynamics of MCF-7 and MCF-10a cells following an acute dose of 10 
Gy γ-rays. Top panel: Clonogenic survival curves of MCF-7 (left) and MCF-10a cells (right). 
Middle panel: changes in cell growth kinetics in MCF-7 (left) and MCF-10a (right) resulting 
from 10 Gy γ-ray exposures. Cell cycle distribution of MCF-10a cells for up to 240 hours post IR 









breast cancer stem cells in MCF-10a cells peaks at 
5 days post IR exposure and declines to background levels thereafter (top panel). CSC 
enrichment at 5 days post exposure is dose dependent with a threshold dose of between 5 and 10 
Gy (bottom panel) in MCF-10a cells and increases significantly between 10 and 20 Gy. Error 
bars represent the standard deviation of the mean and stars (*) represent values which are 






Figure 3.4: Time course of cancer stem cell enrichment of hematopoietic cell lines exposed to 
acute doses of 1 and 4 Gy γ-rays. Percentages of CD34
+
 cells were examined in human 
lymphoblast cell lines WTK1 (top panel) and LCL15044 (middle panel) for up to 120 hours post 




 leukemic stem cells were evaluated following IR in KG1a 
AML cells for 72 hours post exposure (bottom panel). Error bars represent standard error of the 





Figure 3.5: Telomerase inhibition blocks breast cancer stem cell enrichment following IR. Top 
panel: effect of MST-312 telomerase inhibitor on telomerase activity in MCF-7 (left) and MCF-
10a cells (right). Middle panel: cytotoxicity of MST-312 at 48 and 72 hours post exposure as 
determined by MTT assay in MCF-7 (left) and MCF-10a (right) cells. Bottom panel: telomerase 
inhibition blocks radiation induced stem cell enrichment in both MCF-7 (left) and MCF-10a cells 
(right). Error bars represent standard error of the mean and stars (*) represent values significantly 









 osteosarcoma cancer stem cells  in the telomerase 
negative, ALT cell lines U20S and SAOS2 at 5 days post an acute dose of 15 Gy γ-rays. Error 
bars represent standard error of the mean and stars (*) represent values significantly different 










 breast cancer stem 
cell enrichment in MCF-10a cells 5 days post exposure to IR.  Neither TNKS1/Wnt signaling 
inhibitors IWR-1 or XAV-939 were effective at blocking radiation induced stem cell enrichment; 
however, they did significantly elevate background breast cancer stem cell levels. DNA-PKcs 
inhibitor Nu7026 significantly decreased background CSC levels, but did not impact overall 
stem cell enrichment as a result of irradiation. Error bars represent standard error of the mean 
and stars (*) represent values significantly different than unirradiated control and each inhibitor. 
Bars with stars represent values which are significantly different than DMSO (vehicle treated) 
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CONCLUSIONS AND DISCUSSION 
 
Overview 
Since Barbara McClintock and Herman Muller first identified telomeres, researchers 
have sought to understand the role these deceptively simple structures play in a myriad of 
biological processes (McClintock, 1938; Muller, 1938). With the identification of telomerase, the 
reverse transcriptase that elongates telomeres (Blackburn et al., 1989), and recognition of its up-
regulation in the vast majority of human cancers (N. W. Kim et al., 1994), the field of telomere 
biology quickly grew and expanded to encompass numerous fields ranging from aging and 
degenerative disease, to stem cell biology and cancer. We now appreciate that telomeres and 
telomerase lie at the intricate crossroads between normal tissue aging and cancer, and so may be 
critical targets for slowing human aging and winning the war on cancer (Blasco, 2005).  
Telomerase is repressed in the vast majority of human somatic cells, but serves to endow 
replicative immortality to adult stem cells (ASCs) and embryonic/pluripotent stem cells (ESCs) 
(Flores & Blasco, 2010). Additionally, telomerase is reactivated or alternatively cells which 
already contain telomerase activity such as ASC’s are mutated to become cancer stem cells,  
therefore driving carcinogenesis (Shay & Wright, 2011). Thus, as telomerase and telomeres are 
crucial players in carcinogenesis and tumor maintenance, understanding their role in response to 
known carcinogens and cancer therapies will help to identify potential mechanisms with 
potential to aid both the prevention and treatment of cancer.    
Telomeres are critical players in the biological response to radiation as short telomeres 




Azzam, & Sabatier, 2014). Further, dysfunctional telomeres can join incorrectly to DNA double 
strand breaks following radiation exposure thereby contributing to genomic instability (Latre et 
al., 2003). As roughly two in three patients diagnosed with cancer will undergo radiation therapy 
as part of their treatment (Oncology, 2008), gaining a deeper understanding of the interplay 
between telomere biology and radiation exposure will help to identify key processes that can be 
targeted and exploited to improve clinical outcomes. In the studies reported here, we investigated 
the response of telomeres and telomerase to ionizing radiation in both normal and cancer cells.  
Our goal was to 1) characterize the effect of both high and low dose rate (LDR) ionizing 
radiation (IR) on telomerase activity and telomere length in both normal and cancer cell lines, 2) 
more thoroughly define the enrichment of cancer stem cells (CSCs) following IR exposure, and 
3) investigate the potential role of telomeres and telomerase in the radiation induced enrichment 
of cancer stem cells.       
 
Changes in Telomerase Activity Following IR Exposure 
Telomerase, a critical regulator of cellular lifespan (Blasco, 2005; Flores & Blasco, 2010; 
Shay & Wright, 2011), has been shown to be upregulated in a wide variety of primary a0nd 
recurrent tumors following radiation therapy, presenting a critical question; is the upregulation of 
telomerase activity following IR exposure aiding in the accelerated repopulation of tumors 
following radiation therapy? To address this question, changes in telomerase activity in a panel 
of normal and cancer cell lines of both mammary and hematopoietic origin were analyzed. 
Results demonstrated that telomerase activity was elevated in cancer cell lines (high telomerase) 
following exposure to IR, but not in normal (telomerase negative) or immortalized non-
tumorigenic cell lines (telomerase positive) that have a functional checkpoint response. These 




hTERT and hTERC, both of which were upregulated in MCF-7 breast adenocarcinoma cells 
following acute exposures, but downregulated in the non-tumorigenic MCF-10a immortalized 
mammary epithelial cell line. LDR IR exposure yielded slight, but not significant decreases in 
telomerase activity in all cell lines examined, suggesting that the response of telomerase to IR is 
dependent on dose delivery regimen and highlighting the need to address changes in telomerase 
activity in dosing regimens similar to those that occur in fractionated radiation therapy.   
Telomere length in MCF-7 and MCF-10a cells was also evaluated following acute 
exposures to 10 Gy γ-rays. As it was previously reported that cells with short telomeres are radio 
sensitive (Bailey, 2008; Gisselsson et al., 2001), and we observed increased telomerase activity 
in cancer cells, we expected to see a loss of short telomeres due to apoptotic removal of cells 
with short telomeres, and an increase in the population’s overall telomere length. However in 
both MCF-7 and MCF-10a we observed significant shortening of all telomeres within the cell 
population, rather than selective loss of shorter telomeres at the time of irradiation or elongation 
resulting from telomerase activity increases. The overall loss in average telomere length in the 
MCF-7 cells was around 20 percent while the overall loss in MCF-10a cells was closer to 30 
percent. This difference may be explained by the elevation in telomerase activity observed in 
MCF-7 cells that was absent in MCF-10a cells. Thus, while telomerase activity is elevated in 
cancer cells following IR, and this activity appears to help mitigate telomere loss, it did not result 
in an overall elongation of telomeres. This suggests that the response of telomerase following IR 
is may function to mitigate loss of telomere length via its canonical role in telomere elongation; 
however, further investigation is necessary to elucidate its role in tumor repopulation following 
radiation therapy. What is difficult to explain is the overall loss of telomere length suggesting 




telomeres have also been linked to genomic instability, one of Weinberg’s hallmarks of cancer. If 
acute exposure to IR is inducing telomere shortening in both cancer and non-tumor cells, the role 
of such shortening in inducing genomic instability must be examined, as irradiation of non-tumor 
cells during radiation therapy could lead to therapy induced second cancers.   
Implications and Future Directions 
As telomerase activity was elevated in cancer cells following exposure to therapeutically 
relevant, acute doses of IR, it is possible that such an elevation is contributing to accelerated 
tumor repopulation (Pandita & Roti Roti, 2003; Sawant et al., 1999), and therefore may represent 
a viable target in preventing tumor recurrence following radiation therapy. Additionally, IR 
exposure led to an overall shortening of telomeres in both normal and cancer cells, regardless of 
telomerase activity. Therefore, understanding the fundamental consequences of IR-induced 
telomere shortening may be vital to preventing genomic instability in non-tumor tissues exposed 
during the course of radiation therapy. Future studies will seek to characterize the response of 
telomerase and telomere length to radiations of different qualities including heavy charged 
particles found in the deep space environment and those used in carbon ion and proton radiation 
therapy. Such studies will help to define and mitigate the risk these exposures may pose to 
human pioneers in space, as well as to those who receive cancer treatment through carbon ion 
therapy.  
 
Telomerase in the Radiation Induced Enrichment of Cancer Stem Cells 
IR Induced Elevation of Telomerase Activity Precedes Stem Cell Enrichment 





CSC stem cell enrichment following exposure to therapeutically relevant, acute doses of IR in 




2008; Lagadec et al., 2012; Lagadec et al., 2010; Phillips et al., 2006). To our knowledge, we are 
the first to report CSC enrichment in the non-tumorigenic MCF-10a cell line following IR 
exposure. We also report an increase in the percentage of lymphoblastoid cells expressing the 
hematopoietic stem cell (HSC) marker CD34 in response to radiation exposure (Calloni et al., 
2013).  The consequences of such stem cell enrichment are largely unknown, however as CSCs 
are more resistant to radiation therapy and possess increased replicative lifespan, it can be 
inferred that IR induced CSC enrichment may well contribute to accelerated tumor repopulation 
following radiation therapy, as well as drive tumor progression in non-tumor tissues (Butof et al., 
2013; Lacerda et al., 2010; K. Ogawa et al., 2013; Z. Yu, Pestell, Lisanti, & Pestell, 2012).   
Our initial goal was to determine whether the enrichment of CSCs in irradiated MCF-7 
cells correlated with elevations in telomerase activity. Our results revealed that telomerase 
activity was elevated within the first 48 hours post IR exposure in cancer cell lines (expressing 
high levels of telomerase), but not in  non-tumor cell lines (telomerase low or negative). 
Additionally, breast CSC enrichment did not occur until 120 hours post IR exposure. Therefore, 
elevations in telomerase activity temporally preceded the enrichment of CSCs and so was clearly 





CSC populations in the AML cell line KG1a (Bonnet & Dick, 1997; 
Hoang et al., 2012; Perez Mdel et al., 2002), which displayed increased telomerase activity post 
exposure to both 1 and 4 Gy of γ-rays that coincided with decreased CSCs at these same time 
points. Further the non-tumor cells MCF-10a, LCL15044, and WTK1 displayed significant 
increases in the proportion of CSCs despite no change in telomerase activity. This suggests that 





Telomerase Reverse Transcriptase is required for IR Induced Breast Cancer Stem Cell 
Enrichment 
Due to telomerase activity being elevated prior to the enrichment of breast CSCs 
populations following exposure to IR, we reasoned that telomerase may be acting upstream in a 
pathway that promotes CSC enrichment. To test this hypothesis we utilized the small molecule 
inhibitor MST-312 which blocks the reverse transcriptase activity of telomerase (Seimiya et al., 
2002). Indeed, inhibiting telomerase activity blocked the enrichment of CSCs following IR 
exposure in MCF-7 cells. Telomerase inhibition also blocked enrichment of CSCs in MCF-10a, 
despite a lack of elevated telomerase activity following IR, supportive of a causative role.  
Interestingly, in neither MCF-7 nor MCF-10a did telomerase inhibition affect the background 
percentage of CSCs, indicating that inhibition is acting specifically to block a radiation induced 
phenomenon, in this case stem cell enrichment.  
Since telomerase appeared to be playing a critical role, we sought to determine whether 
IR induced CSC enrichment occurred in cancer cells that maintain telomere length through the 
telomerase independent alternative lengthening of telomeres (ALT) pathway (Cesare & Reddel, 





recently identified in the U2OS and SAOS2 cell lines (Tirino et al., 2008; Tirino et al., 2011; L. 
Yu et al., 2013), so we exposed these cells to acute exposures of 15 Gy γ-rays and found that 
CSC enrichment also occurred in the absence of telomerase activity. This gave further 
confirmation that inhibition of telomerase in telomerase positive cancers may be affecting 
upstream pathways in telomerase positive cancers or that loss of telomere integrity through the 





Several candidate pathways may provide insight. It was recently demonstrated that 
telomerase interacts with the Wnt/β-catenin and NF-κB signaling networks, which are known to 
promote “stemness” and block differentiation in colon carcinoma (Choi et al., 2008; Greider, 
2012; Hoffmeyer et al., 2012; Low & Tergaonkar, 2013; Stower, 2012). Several recent reports 
have demonstrated that hTERT is transcriptionally regulated by Wnt/β-catenin signaling; 
however this finding has come under scrutiny, as Blackburn et. al. disputed this claim (Listerman 
et al., 2014). Telomerase has also been implicated as a direct regulator of the NF-κB 
inflammation response, as hTERT binds directly to NF-κB to promote transcription of cytokines 
including IL-6 (Ghosh et al., 2012; Wu et al., 2013). Furthermore, a mode of action through NF-
κB may help explain why CSC enrichment was observed in MCF-10a cells despite an elevation 
of telomerase activity as overexpression of the NF-κB protein was shown to substitute for loss of 
telomerase activity (Ghosh et al., 2012). Future studies will seek to define the link between IR, 
telomerase, and CSC enrichment following IR exposure (Dreesen & Brivanlou, 2007).  
Furthermore, neither inhibition of tankyrase 1 (TNKS1) poly-ADP ribose polymerase 
activity that has been previously demonstrated to induce telomere shortening (Hsiao & Smith, 
2008; Smith & de Lange, 2000; Smith et al., 1998), nor DNA dependent protein kinase c (DNA-
PKcs) kinase activity that is required for efficient end-capping function of telomeres (Bailey, 
2008; Bailey, Brenneman, et al., 2004; Dregalla et al., 2010; Le et al., 2013) were able to prevent 
IR induced enrichment of CSCs. These results suggest that the inability of CSCs to be enriched 
following IR exposure upon telomerase inhibition was specifically due to telomerase activity, 
and potentially telomerase related pathways, rather than disruption of the telomere structure. 
Potential explanations could include increases in the percentage of senescent cells resulting from 




Implications and Future Directions: 
CSC enrichment following IR exposure likely plays a critical role in tumor repopulation 
following radiation therapy. With the finding that stem cell enrichment also occurs in non-
tumorigenic cell lines, it may also be a contributing factor to carcinogenesis and tumor 
progression in non-tumor tissues exposed to IR. We identified telomerase reverse transcriptase 
activity as a critical player in this process; the evidence reported here suggests that telomerase is 
acting through pathways that promote “stemness” rather than due to direct effects at telomeres. 
Future studies will seek to expand on this knowledge and explore potential links to the Wnt/β-
catenin and NF-κB signaling networks.  
 
Implications and Future Directions 
We explored both canonical and potential non-canonical roles for telomeres and 
telomerase in the response of various cultured cell lines to IR exposure. We determined that 
acute IR (γ-ray) exposure elevated telomerase activity in established cancer cell lines. Further we 
suggested that checkpoint activation may be the mechanism responsible for keeping telomerase 
activity under control in IR damaged, non-tumor cells. Telomeres were significantly shortened as 
a result of IR exposure in both normal and cancer mammary epithelial cells, indicating potential 
induction of telomere driven genomic instability that may promote tumor recurrence and 
carcinogenesis following radiation exposure. We also demonstrated that telomerase activity is 
required for the enrichment of CSCs following IR exposure in telomerase positive breast 
carcinoma cells, and suggest that pathways such as Wnt/β-catenin and NF-κB signaling may be 
involved upstream of telomerase to promote stem cell enrichment following IR exposure.   
Taken together, the findings we report here imply that telomerase isn’t just for telomeres 




developed an admittedly telo-centric working model (Figure 1), where telomeres, telomerase, 
and “stemness” are merged with canonical modes of cancer progression including mutation, 
chromosome aberrations, and genomic instability, to highlight the critical role of these 
fascinating structures in the process of carcinogenesis and tumor repopulation following 
radiation therapy.  
The proposed model (Figure 1) builds upon the accepted premise that IR induces 
carcinogenic mutation of normal tissues (telomerase negative), induce telomere shortening, and 
leading to genomic instability as supported by evidence in Chapter 2. IR induced instability can 
lead to further mutation and cancer progression. Additionally, when adult stem cells (telomerase 
positive) undergo oncogenic transformation and/or an adult somatic cells are reprogrammed 
from IR exposure (reactivating telomerase), they can become or evolve into CSCs and propagate 
mutations to progeny leading to bulk tumor formation. In both of these scenarios, IR leads to the 
generation of a bulk tumor (telomerase positive) that must be treated with radiation therapy. That 
treatment can then induce CSC enrichment via selection of existing CSCs and/or through the 
reprogramming of NSCCs into CSCs resulting in tumor regrowth, accelerated repopulation, and 
potential recurrence. Further, radiotherapy poses another risk in that it can spark the carcinogenic 
processes described above in normal tissues irradiated over the course of treatment, leading to 
treatment induced secondary cancers.  
The model proposes that telomerase and the genomic instability arising from the 
generation of short telomeres through IR exposure, are critical drivers in the process of 
carcinogenesis. Reactivation and subsequent deregulation of telomerase via mutation of 
checkpoints for example lead to telomerase activity elevation promoting growth and CSC 




factors that contribute to tumor recurrence and potentially second cancers. Thus, when it comes 
to carcinogenesis and cancer treatment, the reality is much more complex than the long and short 
of telomeres and positives and negatives of telomerase activation. The studies we described here 
highlight and propose new avenues of research building on the appreciation for telomerase and 
telomeres underlying all the hallmarks of cancer.  
Future studies will seek to expand upon those described previously and highlight the 
effects of high LET radiation exposure such as that experienced in the deep space environment 
and as a result of proton and carbon ion based radiation therapy on telomeres and telomerase.  
Additionally we intend to expand our studies of telomerase and telomere length in response to IR 
in apparently healthy stimulated human blood samples and look for evidence of lymphocyte de-
differentiation. Results will have immediate implications for potential health risk assessment in 
astronauts living aboard the International Space Station and beyond. Furthermore, identification 
of pathways and processes outside of telomerase inhibition that that could be manipulated to 





Figure 4.1: Working model depicting the potential role of telomeres and telomerase in ionizing 
radiation induced carcinogenesis starting in telomerase negative adult somatic cells (top portion) 
and telomerase positive adult stem cells (bottom portion). Model depicts the process of ionizing 
radiation induced carcinogenesis effecting telomere length and differentiation state which may 
lead to the development of cancer cells via the multistage model of carcinogenesis or through the 
conversion of an ASC into a CSC. Further treatment of cancer via radiation therapy induces 
similar elevation of telomerase activity and differentiation status, potentially leading to 
accelerated tumor repopulation and tumor recurrence or radiation induced carcinogenesis of 
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